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ABSTRACT

MEDICATION COST AND UTILIZATION IN HOSPICE CARE:
AN ANALYSIS OF 2007 CLAIMS DATA

By
Rachi H. Parekh
May 2013

Thesis Supervised by Dr. Khalid M. Kamal
Objectives:
1. Describe patient-related and hospice-related characteristics such as gender,
average length of hospice stay, primary diagnoses, average daily census, number
of admissions per year, net operating revenues, inpatient unit (IPU) operating
costs, and medication expenditures of hospices in Ohio and compare it with
NHPCO data.

2. Identify and analyze therapeutic drug classes and medications with the most
frequent utilization rates and largest percentage of expenditures in hospice care.

iv

Method:
Hospice Pharmacy Benefit Managers (PBM) employ pharmacists to provide
comprehensive pharmaceutical care services for patients under hospice care and one
component of pharmacist provided services include comprehensive medication review.
To study the impact of pharmacist-led medication review on hospice costs and
medication utilization, PBM claims data for year 2007 were obtained from five hospices
in Ohio. The data included information on utilization and costs of medications, patientrelated (gender, average length of hospice service, and primary diagnoses) and hospicerelated (number of admissions per year, average daily census, net operating revenues,
inpatient unit [IPU] operating costs and pharmacy costs) characteristics. Claims data were
analyzed to identify the most frequently used therapeutic drug classes and those classes
which contributed to the largest percentage of pharmacy expenditures. Prescription drug
count and total cost for medications under the identified therapeutic drug classes were
also obtained. For benchmarking purposes, analysis was conducted to compare patient
and hospice-related data obtained from the five hospices to the 2007 NHPCO data.

Results:
The average number of admissions per hospice for the year 2007 was 627
patients. Average daily census (136 patients) and total patient days (51,350 days) in these
five hospices were 1.5 times higher as compared to that of NHPCO data (90 patients and
31,300 days, respectively.). Annual drug expenditures per hospice ranged from $67,580
to $763,413 while average hospice medication cost per patient per day (PPPD) was
$11.12 ($12.43 PPPD for home care and $8.5 PPPD for nursing care). Average PPPD
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excluding outliers such as enoxaparin was $10.72 ($12.05 PPPD for home care and $8.25
PPPD for nursing care).

Approximately 1,020 different drugs under 246 therapeutic classes were utilized
in the five hospices. The most frequently utilized therapeutic class of drugs, based on
prescription drug volume included analgesic-narcotics (15.6%) followed by laxativescathartics (7.5%), and anti-anxiety drugs (7%). Therapeutic classes contributing to the
majority of drug expenditures, included analgesics-narcotics (16.5%), SSRIs (4.7%), and
anti-anxiety drugs (4.5%). Medications whose frequency of use accounted for high
expense included morphine sulfate (5.3% - utilization, 4.4% - expenditure), lorazepam
(4.4%, 3.1%), furosemide (4%, 0.6%), methadone (3%, 0.9%), and prednisone (3.1%,
0.5%). Medications such as enoxaparin injections whose frequency of utilization was low
(0.01%), contributed to 3.1% of total medication expenditure. Likewise, fentanyl and
oxycodone contributed to 3.5% and 3.7%, respectively to the total medication
expenditure, but their frequency of utilization was only 0.9% and 1.9%, respectively.

Conclusion:
The five hospices in Ohio utilized preferred drugs recommended by pharmacists
following a medication review to identify potential drug related problems (DRPs) and
encourage cost-effective drug utilization. As a result of these interventions, the utilization
of expensive medications is low. Pharmacists specializing in hospice and palliative care
are able to recommend preferred medications in end-of-life care thus producing costsavings. More importantly, hospice pharmacists frequently identify DRP’s which can
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improve patient outcomes. Hospices should consider interventions made by pharmacists
and place emphasis on the utilization of cost effective drugs that can be used among
terminally ill patients to provide a high level of quality care with fiscal responsibility.

vii
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CHAPTER 1
INTRODUCTION

The hospice regulations authorizing Medicare reimbursement for hospice-care
services was issued in 1983 and updated in 2008. Beginning in 1984, there have been
significant increases in both the number of programs offering hospice care and the
number of patients who have received hospice care, especially during the past decade.
According to the National Hospice and Palliative Care Organization (NHPCO), the
number of patients who received hospice care in United States (US) increased from
25,000 in 1982 to 100,000 patients’ in1984.1 In 2006, more than 1.3 million patients
received hospice care from more than 4,500 hospice programs nationwide. 1, 2
Furthermore, pediatric hospice programs have also grown as a result of community need.
Pediatric patients account for approximately 1% of the hospice patients’ served.3

Hospice programs are defined as a program of palliative and supportive care
services providing physical, psychological, social, and spiritual care for terminally ill
persons, their families, and caregivers. 4 Many patients receiving end-stage disease
treatments which have little beneficial effects (e.g., chemotherapy, tube feedings,
parenteral nutrition), require skilled help in transitioning to more useful forms of
supportive care, such as hospice care. 5 The treatment focus is palliative, not curative, and
is based on a biopsychosocial model rather than a disease model of care. 6 Palliative care
is treatment for relief of pain and other uncomfortable symptoms through the appropriate
coordination of all aspects of care to maximize personal comfort and relieve distress. 7
1

Palliative care can be provided outside of a hospice program, however hospice care is
always considered to be palliative care. Hospice care allows the patient to remain at home
for as long as possible by providing support to the patient and family, and keeping the
patient as comfortable as possible while maintaining the patient’s dignity and quality of
life.

Hospice programs render services to both the patient and the family and consider
them as one unit of care. Most hospice care services are provided in home or in inpatient
settings (e.g., hospital, freestanding hospice facility, nursing home). Hospice services
may be provided to patients in all age groups, including children, adults and the elderly. 4
Hospice programs generally include services such as nursing care, physician services,
nurse practitioner services, medical social services, and supportive services in the
patient’s home or in an in-patient environment. Typically, inpatient care is short-term,
and is provided for control of pain and management of acute symptoms (e.g., intractable
nausea, vomiting, seizures), or to provide respite care for relief of the patient’s primary
caregivers. Short-term inpatient hospice care may also be provided in order to prepare the
patient and family for home-care services. 8

Under current Medicare guidelines, a hospice care program is considered to be a
coordinated, interdisciplinary program and generally includes services provided by a
physician, psychologist, social worker, nurses, dieticians, pharmacists, rehabilitation
therapists, including speech, occupational and physical therapists, clergy, and home
health services. Medicare certified hospice programs provide care using a team of people
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who assess the needs of the patient and the family and then develop and maintain a plan
of care that meets those needs. Once a patient is admitted to an approved hospice
program, the hospice provider coordinates all care related to the management of the
patient’s terminal illness. 4 Currently, more than 90% of the hospice programs in the
United States are certified by Medicare. 6

Determining the Need for Hospice Services
The decision to elect hospice care services remains a difficult choice. A common
obstacle to timely referral for hospice services is often the physician’s perception that the
patient and the family are not ready to consider hospice. In addition, predicting the time
of death is difficult and often uncertain.11 Some prognostic indicators of limited life
expectancy are disease-specific while some are not. End-stage diseases such as cancer,
heart failure, pulmonary disease, dementia, and stroke are chronic conditions that
physicians frequently encounter and may require hospice referral. Other illnesses, less
frequently encountered by physicians, which may result in a hospice referral, include
AIDS, liver failure, chronic obstructive pulmonary disease (COPD), Alzheimer’s disease
and amyotrophic lateral sclerosis (ALS).9

In some cases, there may not be a single disease process that limits life
expectancy. General guidelines published by NHPCO, previously referred to as the
National Hospice Organization [NHO], 1996), 9 may be used to help determine hospice
eligibility in selected non-cancer diseases. The guidelines do not predict prognosis;
however, they have been adapted by regulators as standards for hospice eligibility.10
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Other assessment tools used to determine prognosis and hospice eligibility include the
Functional Assessment Staging Scale (FAST), Palliative Performance Scale (PPS) and the
Karnofsky Performance Scale score. 11

Patients who may benefit from hospice services include those who are terminally
ill (i.e., life expectancy is six months or less) and who require services for the palliation
or management of the terminal illness and related conditions. 12 The physician must
certify (i.e., validate) that the patient is terminally ill and has a life expectancy of six
months or less to live, if the disease follows its expected course. Certification from the
physician is generally based on the physician’s or medical director’s clinical judgment
regarding the normal course of the patient’s illness.16 Additionally, since medical
prognostication is not always exact, documentation in the medical record must support
the physician’s clinical judgment.

The following clinical prognostic indicators have been identified as general
predictors of end-stage illness (Royal College of General Practitioners [RCGP], 2006),
and may be included in medical record17:


Multiple co-morbidities with no primary diagnosis,

 Greater than 10% weight loss over six months,
 General physical decline,
 Serum albumin < 2.5 g/dL,
 Reduced performance status (e.g., Karnofsky score < 50%), and
 Dependence in most activities of daily living.

4

In the event of patient survival being longer than six months, the physician must
recertify that the patient is terminally ill for the hospice benefit to continue. The fact that
the patient lives longer than six months, is not a reason to terminate coverage of hospice
services.18

Levels of Hospice Care
Hospice care is defined by the services and care provided, in addition to the
setting in which these services are delivered. According to the Medicare Hospice Benefit,
there are four levels of hospice care available: routine home care, continuous home care,
respite care, and inpatient care. 14 More than 90% of the hospice services in the US are
based in the patient’s home. 15

Routine Home Care: Routine home care is the basic level of care provided by the
interdisciplinary hospice team to support a patient with a terminal illness. It may be
provided in a private residence, a hospital residential care facility, or an adult care home.
It may also be provided in a nursing facility when the facility has a contractual agreement
with the hospice agency. This level of care typically requires fewer than eight hours of
primarily nursing care per day and is based on the patient’s individual needs. The nursing
care need not be continuous. Family members and the hospice team work together to
facilitate the role of family and friends as healthcare providers. Caregivers are taught how
to care for the patient along with care that is provided by home health aids and skilled
nursing. Typically, with this level of care, the nurse monitors the comfort level of the
patient and works closely with the physician to adjust the treatment plan as needed. An
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on-call registered nurse is available to provide phone support and make home visits as
necessary.

Continuous Home Care (CHC): Continuous home care is provided in a patient’s home
and is often provided during a medical crisis that would otherwise require inpatient
admission. For example, patients with out of control symptoms such as dyspnea,
delirium, or pain may receive 24-hour nursing services temporarily until they are stable.
A minimum of eight hours of primarily nursing care is required, half of which must be
provided by a registered nurse, licensed practical nurse or nurse practitioner. The nursing
care need not be continuous.

Homemaker or home health aid services may also be provided to supplement
nursing care. Nursing care in the hospice setting includes but is not limited to observation
and monitoring, in addition to skilled care for pain and symptom control. Hospice
medical directors can make home visits during this time as needed. 13

Inpatient Respite Care: Inpatient respite care is short-term care (i.e., five days or less
per benefit period) that is provided to relieve family members and other unpaid
caregivers who care for the patient in their private residence. Respite care may be
provided in a hospice facility, hospital or nursing home.

General Inpatient Care/ Hospital-based care (HB): General inpatient hospice care is
provided in an inpatient setting for the purpose of managing symptoms or to perform

6

procedures for pain control that cannot be performed in other settings. The inpatient
services may be provided in a hospice inpatient facility, hospital facility, or nursing
facility under the arrangement of a hospice agency. 14

Different Types of Hospice Services
Medicare mandates the following core health professional service teams on the
hospice team:
Nursing Care: These services must require the skills of a registered nurse or a licensed
practical nurse under the supervision of a registered nurse, and must be reasonable and
necessary for treatment of the patient’s illness or injury. Nursing care also includes
services provided by a nurse practitioner who is not considered the patient’s attending
physician.

Medical Social Services: These services are provided by a social worker who is working
under the direction of the physician.

Physician Services: The physician services of the hospice medical director or physician
member of the interdisciplinary team must be performed by a doctor of medicine or
osteopathy.

Counseling Services: Different types of counseling services that may be provided,
include counseling on patient’s diet, bereavement services, psychological services, etc.
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Short-term Inpatient Care: General inpatient care may be required for symptom
management and pain control that cannot be provided in other settings. Inpatient care
may be required for medication adjustment, observation or stabilizing treatment, such as
psychosocial monitoring, or for a patient whose family is unwilling to permit needed care
to be furnished in the home.

Medical Appliances and Supplies: These services include medical appliances and
supplies, drugs and biologicals used by the hospice team primarily for relief of pain and
symptom control related to the patient’s terminal illness.

Home Health Aide Services: Trained home health aides, under the supervision of a
registered nurse, may provide personal care services and/or perform household services
to ensure a safe and sanitary environment in the home.

Physical, Occupational and Speech Therapy: These services may be provided for
purposes of symptom control or to enable the patient to maintain basic functional skills
and activities of daily living. Despite the election of hospice care services for end-of-life
care, specific disease treatment may be required for a secondary illness. These treatments
may be considered life-prolonging; however, they often eliminate adverse symptoms such
as shortness of breath, physical fatigue and edema. Essentially, some treatments may be
both disease-modifying and palliative. Hospice organizations may allow patients to
receive treatments such as palliative radiation or chemotherapy, blood transfusion or even
surgery, if necessary, to control symptoms.19
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Professional Pharmacist services as such are not specifically mandated as a core
requirement. However, the 2008 Medicare Hospice Conditions of Participation do
require the services of a practitioner with the requisite skills to oversee the hospice
medication-use process for hospice patients regardless of the hospice environment of
care. Thus, most hospices today utilize a pharmacist as the health care professional
responsible to the interdisciplinary team to provide oversight of the medication use
process and to provide medication therapy management for the hospice patient. 39

Discharge from Hospice Services
In some situations, it is appropriate to discharge a patient from hospice. If the
hospice team determines the patient is no longer considered terminally ill, discharge from
hospice is deemed appropriate. In addition, hospice discharge may also be appropriate if
the patient refuses services or is uncooperative, moves out of the area, transfers to another
hospice program, or chooses to “revoke” hospice services. 20 To revoke the election of
hospice care, the patient must file a document with the hospice that includes a signed
statement that the patient revokes the election for Medicare coverage of hospice care for the
remainder of that election period and the effective date of that revocation. The patient forfeits
hospice coverage for any remaining days in that election period. Upon revoking the election
of Medicare coverage of hospice care for a particular election period, a patient resumes
Medicare coverage of the benefits waived when hospice care was elected. An individual may
at any time elect to receive hospice coverage. 39 In the event a patient is discharged from

hospice, benefit coverage would be available under core medical benefits as long as the
patient remained eligible for coverage of medical services. 21 It is recommended that the
9

hospice program have a discharge planning process taking into account the possibility a
patient’s condition may stabilize or change, and hospice services would no longer be
required. Furthermore, it is recommended that the patient and family are notified that a
discharge is being considered in order to allow for necessary arrangements. Prior to
discharge, the hospice must obtain a written physician discharge order from the hospice
medical director. 20

Medications as a Component of Hospice Care
Hospice programs use medications, medical equipment and supplies for symptom
control and improvement in the patient’s quality of life. The goal is to promote pain and
symptom management to the greatest extent possible. 19 Each hospice patient presents
unique, rapidly changing symptom clusters, often including pain, weakness, anxiety,
dyspnea, anorexia, constipation, early satiety, fatigue, and dry mouth.22 Because
treatment of hospice care is palliative and time is short, creative aggressive medication
regimens are crucial. As allowed by the Food and Drug Administration (FDA), clinicians
use FDA-approved drugs for any reasonable purpose.23

Pain
Despite available and effective treatments, some generalists fail to assess pain
appropriately, hesitate to prescribe opioids, and hold inaccurate assumptions about pain
tolerance and drug dependency.24 Hospice providers take reasonable pain-management
efforts. Their actions are bolstered by federal guidelines and many states laws affirming
patient’s rights to effective pain management.23
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Pain often has multiple causes such as soft tissue injury, tumors, bone infiltration,
and nerve damage. Because patient’s pain thresholds differ, no standard protocol exists.
Most hospice programs follow the World Health Organization’s 3-step analgesic ladder,
which provides relief for 70% of patients 25, 26 :
 A nonopioid for mild-to-moderate pain
 A weak opioid for moderate-to-severe pain with a nonopioid adjuvant
 A strong opioid for severe pain with a nonopioid adjuvant.

Opioid doses are not reduced solely for hypotension, decreased respiratory rate, or
consciousness; optimal comfort defined by patient preference is the goal. Oral
administration is preferred, to avoid painful injections, but medications can be
administered through a different route if the patient cannot take them orally.27 For bone
pain, approximately, 40% of patients find relief with radiation therapy.28 Adjunctive
therapy is often utilized to help manage other symptoms.30

Patients sometimes plead for rapid death if pain or symptom management is
inadequate.31 In cases of retractable pain, the American Academy of Pain Medicine's
position is unequivocal: “In rare circumstances, when pain and suffering are resistant to
treatment, sedation may be therapeutic and medically appropriate to obtain relief if
consistent with the expressed wishes of the patient.” 32
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Fluid Balance
End-stage intravascular problems often lead to fluid imbalance and edema.
Nausea and vomiting also contribute to imbalances. Rehydration therapy can worsen
edema and lead to skin breakdown.30 Practices such as offering small amounts of liquid
or ice chips are often used as alternatives to intravenous (IV) therapy.30 However, IV
hydration may be employed to hasten excretion of drug metabolites and provide relief.29

Dyspnea
Dyspnea, affecting up to 70% of hospice patients, can be a frightening experience.
Labored breathing, breathlessness, and gasping suggest hypoxia, but most hospice
patients are not hypoxic. Supplemental oxygen may provide little relief. Causes are often
related to pulmonary edema, obstruction, anemia, electrolyte imbalance, cardiac
decompensation, respiratory failure, anxiety, and lymphangitis. If possible, underlying
causes should be corrected. Keeping the room cool, employing stress-management
techniques, and helping the patient relax also help. Low dose opioids and anxiolytics
(usually benzodiazepines) are most commonly used and are effective at relieving
dyspnea.23, 24, 29

Delirium
Delirium, an acute state of confusion, disorientation, and severe cognitive
impairment—may be drug-induced or a consequence of dyspnea, hepatic insufficiency,
vitamin deficiencies, or hypoalbuminemia.24 Haloperidol, risperidone, olanzapine, and
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lorazepam are often helpful. Clinicians might select a more sedating neuroleptic such as
chlorpromazine for patients experiencing refractory delirium.29

Cachexia
Many terminal diseases end with cachexia or wasting. Cachexia is loss of body
mass that cannot be reversed nutritionally, even if the affected patient consumes more
calories, lean body mass will be lost, indicating there is a fundamental pathology in place.
Prevalence varies with pathology; lung cancer and AIDS often cause cachexia.24, 34, 35

Agents that increase protein synthesis and decrease proteolysis often are helpful,
including corticosteroids (which improve anorexia but not cachexia), and megestrol
acetate and the preferred medication, mirtazepine.30

Other Symptoms
Imminent death is heralded by a plethora of problems: constipation, diarrhea, skin
breakdown, infections, and weakened immunity. Each terminal illness presents its own
symptom constellation, many of which are iatrogenic. Not all problems are physical;
anger, depression, and anxiety are common and minimize quality of life. Anxiolytics and
antidepressants fortify psychological supports, but fast onset of action is imperative. For
this reason, clinicians often prefer methylphenidate over other medications requiring
weeks to achieve maximum clinical impact.30

13

Procedures for Dispensing and Administering Medications
Once a patient is certified as terminally ill with six months or less to live and
elects hospice services, an initial plan of care must be established, and all treatment of the
patient’s terminal illness must be provided by or through the hospice. Qualified personnel
must perform all services. 18

The hospice provides appropriate methods and procedures for the dispensing
and administering of drugs and biologicals. Whether drugs and biologicals are obtained
from community or institutional pharmacists or stocked by the facility, the hospice is
responsible for drugs and biologicals for its patients, insofar as they are related to the
terminal diagnosis and for ensuring that pharmaceutical services are provided in
accordance with accepted professional principles and appropriate Federal, State, and local
laws. 38

The procedure for the dispensing and administering of drugs is as follows
(Conditions of participation by CMS):
(1) Licensed pharmacist: It is mandatory for a hospice to employ a licensed
pharmacist; or have a formal agreement with a licensed pharmacist to advise the hospice
on ordering, storage, administration, disposal, and record keeping of drugs and
biologicals. 39
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(2) Orders for medications: It is the responsibility of a physician to order all
medications for the patient. For verbal medication orders, the physician must deliver the
orders to a licensed nurse, pharmacist, or another physician; then the individual receiving
the order must record and sign it immediately and have the prescribing physician sign it
in a manner consistent with good medical practice. 41

(3) Administering medications: Medications should be administered only by one of
the following individuals:
(i) A licensed nurse or physician.
(ii) An employee who has completed a State-approved training program in
medication administration.
(iii) The patient if his or her attending physician has approved.

(4) Control and accountability: The hospice must have procedures for control and
accountability of all drugs and biologicals throughout the facility. Drugs should be
dispensed in compliance with Federal and State laws and records of receipt and
disposition of all controlled drugs are to be maintained in sufficient detail to enable an
accurate reconciliation. It is the duty of the pharmacist to determine that drug records are
in order and that an account of all controlled drugs is maintained and reconciled. 41

(5) Labeling of drugs and biologicals: The labeling of drugs and biologicals is based
on currently accepted professional principles, state and federal regulations, and includes
the appropriate accessory and cautionary instructions, as well as the expiration date when
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applicable.

(6) Storage: In accordance with State and Federal laws, all drugs and biologicals are to
be stored in locked compartments under proper temperature controls and only authorized
personnel may have access to the keys. Separately locked compartments should be
provided for storage of controlled drugs (Schedule II of the Comprehensive Drug Abuse
Prevention & Control Act of 1970) 42 and other drugs subject to abuse, except under
single unit package drug distribution systems in which the quantity stored is minimal and
a missing dose can be readily detected. An emergency medication kit is kept readily
available.

(7) Drug disposal: Controlled drugs no longer needed by the patient are disposed of in
compliance with State requirements. In the absence of State requirements, a pharmacist
and a registered nurse dispose the drugs and prepare a record of the disposal.41

Value of Pharmacists in Hospice Care
The American Society of Health-Systems Pharmacy (ASHP) suggests that highquality hospice and palliative care requires both, traditional and expanded pharmacist
activities, including a variety of clinical, educational, administrative, and support
responsibilities such as 40:


Assessing the appropriateness of medication orders and ensuring the timely
provision of effective medications for symptom control



Counseling and educating the hospice team about medication therapy
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Ensuring that patients and caregivers understand and follow the directions
provided with medications



Providing efficient mechanisms for extemporaneous compounding of nonstandard
dosage forms



Addressing medication related financial concerns



Ensuring safe and legal disposal of all medications after death



Establishing and maintaining effective communication with regulatory and
licensing agencies

A pharmacist can also be useful in improving the cost-effectiveness of
pharmacotherapy for symptom control in hospice care through patient-specific
monitoring for drug therapy outcomes, recommending alternative drug products and
dosage forms, minimizing duplicative and interacting medications, compounding of
appropriate medications, improving drug storage and transportation, and educating staff,
patients, and families about the most effective ways of handling and using medications.
Systems for documenting these activities and determining cost-effectiveness/cost–
benefit/cost–utility ratios of medications used in the care of terminally ill patients are
needed. Avoidance of admissions to hospitals or long-term-care facilities through
improved symptom control is a highly desirable and cost-effective outcome of
pharmaceutical care for hospice and palliative care patients.
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PROBLEM STATEMENT

Clinical pharmacists at hospices see an average of 10 drug-related problems per
patient upon admission.57Studies have shown that as polypharmacy increases, the rate of
drug-related problems increases as well.57 A few of these problems include medications
prescribed with no indication, potential or actual adverse drug reaction detected, dose too
high, dose too low, medications indicated but not prescribed and inappropriate
medications..

If the medication is not appropriate for the patient, this may result not only in
unnecessary medication costs, but also result, in high costs, and unnecessary suffering
associated with untreated symptoms. For example, the use of antiemetics for
nausea/vomiting due to constipation from opioids will be poorly efficacious and not costeffective. Since the root cause of the symptom (nausea/vomiting) is constipation,
medication for constipation should be prescribed, such as a laxative instead of an
antiemetic.

The appropriate selection of medications results in better symptom control, fewer
nursing visits, fewer on-call demands, fewer hospitalizations and ER visits, and fewer
medication-related liability issues. The use of unnecessary medications should be avoided
in terminally ill patients, and hospice programs should not be burdened with costs related
to unnecessary medication use, which can be easily avoided.
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All hospices should consider employing clinical pharmacists. Some hospices
employ full–time pharmacists, while others sub-contract for this service. Employing
clinical pharmacists through the relationship of a Pharmacy Benefit Manager (PBM) for
reconciliation of medication may be considered as the best option. United States PBMs
administer prescription drug plans which provide over 3 billion prescriptions) for more
than 210 million people (70% of entire U.S. population) as part of health coverage
provided through Fortune 500 employers, health insurance plans, labor unions, and
Medicare Part D.62 There are PBMs that partner exclusively with hospices and provide
numerous services pertinent to hospices, such as clinical consultations, education
programs, management reports and summaries including but not limited to drug
utilization review reports.

PBMs emerged in the 1980s, primarily to provide cost-effective drug distribution
and claims processing for the healthcare industry. The PBM industry further evolved in
response to the significant escalation of healthcare costs in the 1990s, as sponsors of
benefit plans sought to more aggressively contain their costs. PBMs developed strategies
to effectively influence both supply and demand. Through purchase discounts, retail
pharmacy networks, mail order pharmacy services, preferred drug list administration,
claims processing and drug utilization review, PBM companies created an opportunity for
health benefit plan sponsors to deliver prescription drugs in a more cost-effective manner
while improving compliance with recommended guidelines for safe and effective drug
use.
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Despite many of advantages of PBMs, many hospices remain reluctant to employ
PBMs for medication review. Successful medication related interventions can bring
substantial cost savings and effective therapies in hospice care. Further studies need to be
conducted focusing primarily on the utilization and costs of medications, or impact of
pharmacist-led intervention leading to cost-effectiveness in hospice care.

OBJECTIVES OF THE STUDY

The overall objective of this study was to identify and analyze medication related
costs as well as medication utilization in hospice care.
The specific objectives were:

1. Describe patient-related and hospice-related characteristics such as gender,
average length of hospice stay, primary diagnoses, average daily census, number
of admissions per year, net operating revenues, inpatient unit (IPU) operating
costs, and medication expenditures among hospice patients.
2. Compare patient-related and hospice-related characteristics of five hospices in
Ohio with National Hospice and Palliative Care Organization (NHPCO) data.
3. Identify and analyze therapeutic drug classes with the most frequent utilization
rates and largest percentage of expenditures in hospice care.
4. Identify and analyze utilization and cost for medications in hospice care.
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CONCEPTUAL FRAMEWORK

For our study, five hospices in Ohio agreed to participate and were requested to
send their 12-month medication cost and utilization data. These five study hospices are
non-profit organizations that employ a pharmacy benefit manager (PBM) for prescription
drug programs. A PBM is a third party administrator of prescription drug programs. They
are primarily responsible for processing and paying prescription drug claims. They are
also responsible for developing and maintaining the medication formulary, contracting
with pharmacies, and negotiating discounts and rebates with drug manufacturers. PBMs
contract with managed care organizations, self-insured employers, insurance companies,
unions, Medicaid and Medicare managed care plans, the Federal Employees Health
Benefits Program and other federal, state, and local government entities to provide
managed prescription drug benefits. Due to their larger purchasing pool for prescription
drugs, PBMs can negotiate rebates and discounts on behalf of their clients.

The PBM claims data have an advantage, for they can be used for a variety of
purposes, including studying the care received by dying patients. Claims data generally
encompass a wealth of variables which facilitate ease in identifying diagnoses and
procedures, help in broadly looking at timing (specific days for hospitalizations, length or
span of days for hospice, home care), and to determine intensity of hospice care (routine,
continuous, or inpatient).

For this study, PBM claims data were employed to conduct a retrospective study.
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PBM claims data consist of information on drug costs and prescription drug count. Such
claims data were collected and obtained from five hospices in Ohio. Annual data from
January 1, 2007 through December 31, 2007 of the five hospices were combined to form
a dataset which contains information regarding prescription medication utilization and
their costs, including information on therapeutic class of medications, drug names, total
cost and prescription medication count. The dataset comprises of at least 1,020 different
medications classified under 250 (approx.) different therapeutic classes of medications.

Additionally, hospice participants were asked to report data for the most recently
available 12-month period, patient-related (gender and average length of stay) and
hospice-related (number of admissions per year, pharmacy costs, physician salary,
nursing salary and bereavement costs) characteristics. These reports were obtained
individually from each hospice which assisted to understand patient demographics and
the overall costs incurred in a hospice.

Retrospective analyses of these PBM claims data were conducted to identify
expensive specialty and even inexpensive maintenance medications. Such analyses can
be conducted quickly regardless of the huge sample size of claims database and are
relatively inexpensive to perform. These analyses helped identify the ten most frequently
utilized and expensive therapeutic classes of drugs in a hospice. Furthermore, they also
allowed us to examine the differences in prescription drug count and total cost by
therapeutic class and by drug name for each hospice and for all hospices combined.
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Besides, medication data from the five hospices were compared to one another to
examine difference in medication use by hospices.

NEED FOR THE STUDY

The overall costs for hospice care to Medicare, other third party payers and
patients may be less as compared to the costs incurred by conventional care, but the cost
for medications in a hospice program could be high, which can be effectively reduced by
medication review. Especially, with the introduction of the Affordable Care Act (ACA), it
has become imperative for all health care institutions to provide patients with high quality
services with minimal costs. Pharmacists specializing in hospice and palliative care are
able to recommend appropriate and effective drug therapy as an alternative to high cost,
high risk medications and produce cost-savings. The pharmacists also identify drug
related problems (DRPs) which can influence better patient outcomes in hospice care.

A technique to ensure that hospice patients gain maximum benefit from their
medications, while simultaneously reducing the potential for harm and improve health
outcomes is essential. Achieving these goals is at the heart of successful medication
review that has been defined as a structured, critical examination of a patient's medicines
with the objective of reaching an agreement with the patient about treatment, optimizing
the impact of medicines, minimizing the number of medication-related problems, and
reducing waste.
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It has also been assumed, although based on little high quality evidence, such
measures will lead to important gains for health systems by reducing hospital admissions
and inappropriate drug prescribing. Such gains hold great appeal for policymakers when
taken in combination with the apparent benefits to patients.5 With this underpinning
rationale in mind, medication reviews have been widely introduced and are increasingly
undertaken by pharmacists operating separately from the physicians involved in
prescribing decisions.

Over the past five years, clinical trials have shown growing evidence of better
outcomes generated due to interventions such as pharmacist-led medication review. These
trials have varied in terms of target population (older people generally, or those with a
specific disease), numbers of pharmacists, and location of the intervention (home,
pharmacy, general practice, hospital, or a hospice). The primary outcome has also varied,
including reduction of drug related problems, adverse drug reactions, hospital
admissions, and/or improving medication appropriateness.65

Medication review, like medications themselves, has the potential to yield
benefits. This intervention delivered by professionals not primarily responsible for
prescribing decisions such as Pharmacy Benefit Managers (PBM), should be expected to
adequately demonstrate not just effectiveness but also cost-effectiveness before being
introduced more widely. PBMs employ variety of tools to demonstrate and produce
effective pharmacy benefit management, thereby recommending utilization of costeffective medications. Formularies are central to these management efforts. By placing
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such cost-effective medications on hospice formulary, PBMs facilitate control of costs to
hospices.

Previous studies have evaluated the impact of pharmacist-led interventions in
terms of clinical outcomes. However, there is a dearth of information related to
economics of medications in hospice care. Thus, there is a need for studies that place
emphasis on reviewing and analyzing the costs and utilization of usage of medications.

Since the five hospices in Ohio employ preferred drugs recommended by
pharmacists following a medication review to identify potential drug-related problems
(DRPs) and encourage cost-effective drug utilization, this study will provide an in-depth
knowledge of the cost of medications in hospice and study the impact of pharmacist-led
interventions on cost savings in hospice care. In addition, PBM claims data obtained
would have important implications for pharmacist’s interventions facilitating
identification of important medications utilization issues that contribute to significant
expenditures in hospice care, which will serve as a benchmark in the field of hospice.
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CHAPTER 2
LITERATURE REVIEW

A comprehensive review of the literature on hospice care in United States was
conducted to identify articles published from 1984 to 2007. The articles were accessed
from search engines such as Medline and Google Scholar. Initial or primary searches
were made using the keywords ‘hospice care’ which resulted in a total of 3,674 articles,
out of which only 59 articles were found to be useful for the study. After reviewing those
articles, only 16 articles relevant to costs and medication utilization of hospice care were
used for the study. Further secondary searches were made using keywords such as
‘hospice medication use/utilization’, ‘hospice drug use’, ‘palliative care medications’,
‘hospice patient characteristics’, ‘hospice care costs’, ‘hospice care economics’, ‘hospice
cost-effectiveness’, ‘terminally ill costs’, ‘terminally ill economics’, ‘pharmacists and
hospice’, ‘pharmacy benefit management and hospice’, and ‘pharmacist-led intervention
and hospice’. A combined total (articles found from primary and secondary
investigations) of 27 articles were used in this research paper.

The term ‘hospice’ was coined hundreds of years ago, but has become familiar
worldwide only recently. The term “hospice” was used in the 1800s for places where
travelers used to rest. It was only later in early 1900s that hospices were used to provide
care for the dying or terminally ill through simple palliative and supportive services. The
first hospice program in the US was established in 1974. Hospices promoted peace,
comfort, and dignity, rendering philanthropic support to provide care to terminally ill or
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dying patients. Furthermore, hospice emerged as a philosophy or concept of care and the
use of hospices increased drastically after the provision of partial reimbursement to
Medicare hospice patients by Federal Legislation (1983).43

It was after 1983, that several research studies on hospice care were conducted,
that focused on the characteristics of patients using hospice services and on the
economics of hospices. The first major development in the structure of hospice services
was the National Hospice Study (NHS, 1984).44 In the course of this study, definition and
structure of hospices emerged. This study provided data on hospice patient characteristics
and expenditures which demonstrated that the model of hospice which evolved from the
original philosophy, under Medicare guidelines, differed substantially in services and
structure from conventional medical care of the terminally ill or dying patients. Several
studies were conducted later on a smaller scale that examined the same or various aspects
of hospice care.

Characteristics of Hospice Patients
Hospice services are available to any individual electing the service regardless of
his/her age, race, marital status, income level, diseases, etc. In recent years, there has
been considerable increase in the use of hospice services by younger patients (younger
than 65 years). In 2006, an estimated 17% of patients younger than 65 years were
receiving hospice care compared to less than 10% in 1984.45

Low hospice care utilization rates have been observed among the non-Caucasian
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population. The number of African-American patients utilizing hospice services dropped
from 8.1% in 2002 to 7.5% in 2005, although, this percentage moved up to 8.2% in
2006. Several causes for underutilization among the African-Americans and other ethnic
minority groups have been proposed. These include the lack of knowledge about hospice
services, different cultural beliefs; and high costs of health care. 46

Utilization of hospice services is affected by geographical location. Previous
studies suggest that utilization of hospice services is positively associated with ‘urbanity’
indicating that more patients utilize hospice services in urban areas than in rural areas.
This positive association with urbanity in the utilization of hospice service is potentially
due to the lack of awareness about hospice services in rural areas; and that there is more
awareness among the urban population which leads to more utilization & expenditures on
health-related issues as compared to rural population. 47

Length of Stay in Hospice/Length of Hospice Service (LOS)
Typically, the length of hospice stay or length of hospice services (LOS) is not
longer than 90 days. The place of delivery of hospice service largely influences the LOS.
It was observed that the inpatient respite care and hospital-based care have shorter LOS
compared to home-based care. The skewed length of hospice service was found to be
72.5 days for hospice service rendered at home and 62.3 days for hospice service
rendered at hospitals.48 Medicare hospice data shows that the LOS for Medicare hospice
recipients decreased from early 1990s to 2001. 49 (Refer Figure 1)
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Figure 1. Variation in length of service provided to Medicare hospice recipient.

29

Disease Diversity Among Hospice Patients
Patients suffering from various diseases can elect to receive hospice care. Unlike
previous years, when hospice programs were in the process of nationwide establishment
(1985), cancer patients accounted for most (90%) of the population; now, a higher
number of non-cancer patients are observed electing for hospice services. These may
include patients suffering from various non-cancer diseases such as heart diseases, lung
diseases, dementia including Alzheimer’s disease, stroke, coma, HIV/AIDS, liver
diseases, etc.50 In 1992, non-cancer patients accounted for 24% of all hospice patients.
Furthermore, based on 2006 NHPCO estimates, the percentage for non-cancer patients
electing hospice services has grown steadily from 39% in 2000 to 50% in 2002 to 55.9%
in 2006. 51 (Refer Figure 2)

Cost of Hospice Services
The Hospice Association of America suggests that the overall cost of hospice care
per patient increased from $3,020 (1989) to $ 6,228 (2001) (Refer Figure 3).52 With this
kind of rising cost of health care, a considerable concern in the US has emerged in the
past decade. Efforts have been made to minimize health care costs, which in turn impose
pressure on the hospice, to deliver optimum care to patients at a lower cost.53
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Figure 2. Variation in proportion of cancer patients versus the proportion of noncancer patients enrolled in hospice programs from 1985 to 2006.
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Figure 3: Costs of hospice care per patient in the United States from 1989 to 2001.
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Medication Utilization
Pain management and symptom control are two of the most important goals of
end-of-life care, and the use of opioids for this purpose is extremely common in hospices.
Previous studies have suggested morphine to be the most utilized drug for pain control.
Approximately, 70% of hospice patients receive morphine for pain control. Moreover, a
fairly strong correlation exists between morphine dosage and some clinical-demographic
data. A study revealed that male and nonwhite patients required slightly higher dosages
than others.25 In addition, primary breast and genitourinary cancers, as well as metastases
to bone and spinal diseases, were associated with higher morphine dosages. 54 Other
analgesic medications that are most commonly used in a hospice setting are long-acting
morphine sulfate (25.4 %), acetaminophen and hydrocodone combinations (20.1 %) and
NSAIDS (17.1 %).55

Constipation is a common problem for hospice care patients and can generate
considerable suffering for patients due to both the unpleasant physical symptoms and
psychological preoccupations that can arise. Constipation may arise as a side-effect of
opioid therapy. 57 In an effort to find a relationship between laxative use and opioid use
among the terminally ill patients, Sykes (1998) found that laxatives were required by
87% of patients taking oral strong opioids and 74% of those on weak opioids. The most
commonly prescribed laxatives/cathartics were senna, docusate sodium, etc.58

Anxiety and depression are other commonly observed symptoms among
terminally ill patients. These symptoms are experienced among a quarter of terminally ill
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patients. Patients may be treated by use of anti-anxiety medications and antidepressants at
a hospice. However, use of the antidepressant medications for treating depression and, in
some cases, anxiety disorders has not been well studied in hospice. Some of the
antidepressant medications may also serve as adjuvant therapy in pain management.59

A study by Williams (1999) analyzed the antidepressants prescribed among the
terminally ill. It was found that the majority of patients who were on anti-depressant
medications suffered from cancer such as lung cancer (26%), breast cancer (43%),
colorectal cancer (15%) and prostate cancer (11%). The most commonly prescribed
medications were selective serotonin reuptake inhibitors (70%) and tricyclic
antidepressant medications.60

When all other possible interventions have failed for the relief of one or more
intractable symptoms (physical, psychological and spiritual) and when relief of refractory
symptoms need to be achieved in terminally ill patients, palliative sedation must be
considered. Rosseau PC (2004) studied the medication utilized for palliative sedation in
hospice care. Benzodiazepines and barbiturates were found to be the most commonly
administered medications for achieving palliative sedation in terminally ill patients.
Midazolam, lorazepam, haloperidol, pentobarbital, phenobarbital and propofol were the
recommended medications for achieving palliative sedation. 56

A study by Haughtevd and colleagues (1994) made efforts to evaluate the cost to a
hospital pharmacy department of providing pharmaceutical services for a hospice
program. Drug acquisition costs were tabulated for all prescriptions dispensed to patients
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in the hospice program from April 1, 1992, to March 31, 1993. Direct time studies were
conducted to determine the average personnel time involved in dispensing a prescription
for a hospice patient. To determine the personnel time associated with auxiliary activities,
self-reporting and work-sampling techniques were used. Indirect and delivery costs were
also calculated. Relevant resource inputs were identified, measured, and valued by using
both observation and pharmacy records. A total of 5,640 hospice prescriptions were
dispensed by the outpatient pharmacy; representing 30% of all prescriptions dispensed.
The average cost of dispensing a hospice prescription was $14.91.The total annual cost of
providing pharmaceutical services to the hospice's patients was $196,607, and the total
annual reimbursement received from the hospice program and self-paying patients was
$155,623; therefore, costs exceeded revenues by $40,984. The cost to a pharmacy
department of providing pharmaceutical services to patients in a hospice program
substantially exceeded revenues. 61

In general, very few studies have looked into the areas of medication utilization,
especially the costs of these medications for hospices. Since there were no data
describing these costs for hospice programs in 2004, Nowels and colleagues (2004)
conducted a cross-sectional survey study in hospices of the Population-based Palliative
Care Research Network (PoPCRN). PoPCRN was formed in 1998 at the University of
Colorado, Denver School of Medicine as a means for conducting on-going studies of care
at the end of life. Specifically, their aim is to facilitate structured and rigorous exploration
of issues of importance to patients, families, caregivers, and providers in palliative care
and hospice settings. Since its inception, PoPCRN has grown to include 279
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hospice/palliative care organizations from 49 states in the United States and also includes
Canada, Australia, Italy, Portugal, and the UK.

The Web-based survey consisted of 31 questions describing structural and
operational features of respondent organizations, aspects of the supply and delivery of
pharmaceuticals for hospice patients, cost controls employed by the respondent
organization, drug costs per patient per day (PPPD), perceived trends in drug costs, and
factors contributing to those trends. Participating hospices were asked to report their most
recent 12-month data. The study analyzed data from 34 hospices concerning their
pharmaceutical cost trends. Most respondents reported higher pharmaceutical-related
costs between 1998 and 2002, but a significant minority reported that their costs had
decreased.

Pharmaceutical costs reported in the 2004 study varied by patient setting with
median daily costs of $8 (long-term care setting from), $11 (home-care hospice setting),
$11.31 (routine level of care), $15 (general inpatient care), and $18 (inpatient care). The
respondents identified a variety of medications and their delivery systems as contributing
to their major medication costs. Long-acting opioids and continuous-infusion delivery
systems were the two most significant contributors. Strategies to control errors included
screening drug on admissions, a preferred drug list, a consulting pharmacist, efficacy
criteria for continuation of high cost drugs, a formulary, a pharmacist on staff of hospice,
and more restrictive admission policies. Certain restrictions were developed on some
drug classes such as cell stimulants, chemotherapy, total parenteral nutrition,
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bisphosphonate, anticoagulants, cardiac pressor agents, intravenous fluids for hydration,
opioids-long acting, antibiotics, continuous infusion, and parenteral medications.62

Lee and McPherson (2006) studied the value of pharmaceutical care
recommendations made by consultant pharmacists and their outcomes. The study was
conducted at three hospice programs, and the investigators were consultant pharmacists
who shared the responsibility of providing drug therapy recommendations to these three
programs. They conducted literature searches to determine if any tools had been
developed to evaluate recommendations made by pharmacists in clinical practice settings.
One tool was identified and adapted for use in a hospice clinical setting. Drug-related
problems (DRPs) (n = 98), clinical interventions (n = 87), and outcomes data were
collected by two hospice consultant pharmacists and evaluated by a panel of experts
using the assessment tool. Ninety-eight interventions were collected and evaluated.
Eighty-seven of the 98 interventions were classified as clinical interventions with specific
therapeutic goals established. Of these 87 interventions, 73 (84%) were accepted by the
prescriber and 56 (77%) out of the 73 helped achieve the therapeutic goals. An additional
of 6 (8%) interventions partially achieved the therapeutic goals. Over 75% of all of the
pharmacists' recommendations achieved their intended therapeutic effect, which resulted
in better management of the patients' physical symptoms. None of the accepted
recommendations resulted in the patient having an adverse effect. Overall agreement
between raters for severity and value was moderately high, 60-70% and 63-80%,
respectively.63
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Guignard (2003), studied the economic impact of community pharmacists'
interventions following the detection of problems related to nonsteroidal antiinflammatory drugs (NSAIDs), whether in a prescription or self-medication format. The
evaluation focused on the gastroduodenal adverse events that could be avoided and the
subsequent savings of healthcare resources spent on treating these adverse effects. A
previous study conducted during a 12-week period in 924 French community pharmacies
provided the number of interventions for drug-related problems concerning NSAIDs. A
simulation model was constructed to compare 2 strategies: a systematic pharmacist's
intervention and the absence of intervention. The base-case patient was assumed to have
been taking an NSAID for 3 months. The model's inputs were extracted from medical
literature and from an institutional medical database. In this study, 608 interventions were
the results of NSAID-related problems. All of these interventions reduced the risk of
gastrointestinal adverse events and avoided a total cost of Euros37, 300. This model
indicated that the dispensing of NSAIDs by pharmacists and related pharmaceutical care
activities have a positive impact by reducing the number of gastrointestinal complications.
The model quantifies the costs thus avoided. It also underlines the necessity of effective
collaboration between the prescriber and the pharmacist if optimal patient management is
to be achieved. 64

The above studies suggest that greater efficiencies, a change in the pricing
structure, or both may be necessary to control drug costs. However, this is possible by
employing a consultant pharmacist or a pharmacist on staff of the hospice. High-quality
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hospice and palliative care requires both traditional and expanded pharmacist activities,
including a variety of clinical, educational, administrative, and support responsibilities.

Our study is based on analyzing the utilization and costs of medications in
hospice care that employ PBMs to manage drug benefits and it would be interesting to
observe the cost-savings produced by these hospices.
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CHAPTER 3
METHODOLOGY

Previous chapters illustrated the role of pharmacists in hospice care and the PBMhospice relationship. This chapter will discuss the data used for the study and the
methods used to achieve the study objectives.

Pharmacy Benefit Manager’s (PBM) claims data are one of the “best sources” of
information for identifying key components of an effective pharmacy plan and for
measuring results that reside within the data. It facilitates conducting retrospective
analysis to not only find medication utilization and costs, but also help in predicting
future costs, trends and needs.

To study our objectives, five hospices in Ohio agreed to participate in the research
study and made their PBM claims data available to the researchers. These hospices
employ a PBM with consultant pharmacists to review medications, plan a formulary, and
help reduce medication costs. PBM claims data for year 2007 (January 1, 2007 through
December 31, 2007) were obtained individually from these five Ohio hospices and
combined into a single dataset. The data was received in Excel format which was sorted
by number of prescriptions in descending order (Prescription [Rx] Count). The data
provided retrospective insurance claims data for the prescriptions fills of patients served
by the five hospices. The study was then conducted post approval of Duquesne
Institutional Review Board.
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To maintain confidentiality, the five hospices were named hospice 1, hospice 2,
hospice 3, hospice 4, and hospice 5. The dataset reflects utilization and expenditures
related to 246 therapeutic classes and 1,020 medications utilized in these five hospices
and is comprised of different variables such as therapeutic class, drug names, prescription
count (Rx Count), and total cost. These variables helped identify therapeutic classes and
medications that contribute to most frequent utilization rates and largest percentage of
expenditures in hospice care. These variables were defined for the study as follows:

Therapeutic Class of Drugs
The medications utilized in each of the hospices are classified under 246 different
therapeutic classes. This variable will help identify the different therapeutic classes of
medications utilized in hospice care.

Drug Names
Drug names are the prescription medications dispensed to a hospice patient served at a
hospice agency. The data includes information on 1,020 different drug names and these
drug names were generic, brand or both. This variable was used to identify the important
medications categorized under different therapeutic classes.

Prescription (Rx) Count
Each dataset received was sorted by prescription count. This variable is defined as the
total number of prescriptions dispensed for each medication in a hospice. It is an ordinal
variable and the value of Rx count ranges from 1 - 990.
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Total cost
This variable is defined as the sum of the cost of prescriptions for each medication. It is
an ordinal variable. In the study, this variable was used to compute the total cost for all
medications prescribed in a hospice and was also used to identify important therapeutic
classes and medications with largest percentage of expenditures.

STATISTICAL REPORTS

In addition to the claims data, statistical reports for hospice patient-related
(gender, primary diagnoses, and average length of stay) and hospice-provider (number of
admissions per year, average daily census, total patient days, nursing salary, physician
salary, bereavement costs and pharmacy costs) characteristics were obtained separately
from each hospice. A mean for each of these characteristics obtained from the combined
data of five hospices was reported and compared to 2007 National Hospice Palliative
Care Organization (NHPCO) data. .

NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION (NHPCO)
REPORTS

Founded in 1978, the National Hospice and Palliative Care Organization is the
oldest and largest nonprofit public benefit organization devoted exclusively to hospice
care. NHPCO is dedicated to promoting and maintaining quality care for terminally ill
persons and their families, and to making hospice an integral part of the U.S. health care
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system. NHPCO collects data annually from nationwide hospices to provide reports or
summary on different aspects of hospice care such as characteristics of patients and
hospice-provider, costs components of hospice care, etc.

In order to compare the hospice in Ohio with hospices nationwide, the 2007
NHPCO Facts and Figures Report was utilized. NHPCO provides comparative reporting
for the following tools that evaluate clinical care and services: the Family Evaluation of
Hospice Care (FEHC), the Family Evaluation of Bereavement Services (FEBS), the
Family Evaluation of Palliative Care (FEPC), and the End Result Outcome Measures
(EROM). NHPCO offers agency and national level reporting for the Survey of Team
Attitudes and Relationships (STAR), the only job satisfaction tool specific to the hospice
field. NHPCO also provides results for the National Data Set (NDS) that are reported at
the national and state level. Both STAR and the NDS are valuable organization and
program evaluation tools.

In order to address the objectives of the present study, the 2007 annual report of
NDS was utilized. The NDS is comprised of program level descriptive statistical
information that provides a comprehensive picture of hospice operations and care
delivery. NDS data are used to answer key questions such as who is providing hospice
care, who are the patients receiving that care, and how much and what kind of services
were provided. NHPCO releases its findings on an annual basis to the media and key
governmental agencies as well as members.
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The primary source of these findings are the hospice and palliative care providers
who participate in NHPCO’s National Data Set (NDS), an annual online survey
supported by many of their state organization partners. Data from the NDS survey is
supplemented by information NHPCO gathers from other sources. In general, the fact and
figures report provides an annual overview of important trends in the growth, delivery
and quality of hospice care across the country. The overview provides specific
information on:
 Hospice patient characteristics (e.g., total patients served, gender, age, ethnicity,
race, primary diagnosis, and length of service);
 Hospice provider characteristics (e.g., total number of providers, organizational
type, size, and tax status);
 Location and level of care; and
 Role of paid and volunteer staff.
Hospice Patient-related Characteristics
Hospice patient-related variables that were included in the analysis were gender,
length of service (LOS) and primary diagnoses. These variables are described as:

Gender
The variable is described as indicator of sex, and is utilized in this study to identify the
gender of the hospice patient.
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Length of Service (LOS)
Mean LOS and median LOS were obtained from the hospices to find the average LOS
provided to hospice patients. LOS is calculated from the date of enrollment to hospice
service until the death or discharge of the patient from the hospice service.

Primary Diagnoses
Primary diagnoses were used to identify the terminal disease, for which is the reason for
which they were enrolled for hospice care. Primary diagnoses were categorized into
cancer and non-cancer. Non-cancer category was further sub-categorized into heart
diseases, dementia/Alzheimer, lung diseases, kidney diseases, HIV/AIDS, stroke/come,
ALS, debility unspecified and other.

Hospice Provider-related Characteristics
These include all the characteristics of a hospice agency such as average daily
census, number of admissions per year, total patient days, net operating revenues per
year, annual inpatient unit operating costs, annual pharmacy costs, physician salary,
nursing salary and bereavement costs.

Number of Admissions Per Year
It is defined as the total number of patients enrolled for hospice services per year.

Average Daily Census (ADC)
Average daily census represents the average number of eligible patients receiving hospice
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care service on a given day, inclusive of all patients receiving home care and in inpatient
unit. In general, it is the average of all patients enrolled for hospice care per day
regardless of the place where service is provided.

Net Operating Revenues
This is the amount accrued by net sales or other regular income related to the operations
of a hospice care agency.

Inpatient Unit (IPU) Operating Costs
This term includes the costs that are associated with all the services provided at a hospice
inpatient unit such as cost of a room/bed.

DATA ANALYSIS

The data analysis was conducted using SPSS (version 15.0). The data was
transferred from Excel to SPSS for ease of manipulating data and conducting statistics.
Data were then checked for accuracy and missing data or incorrect data (3%) were
deleted. The first two objectives of the study were achieved by conducting a statistical
report for year 2007. For all the other study objectives, PBM claims data from all study
hospices combined for year 2007 was utilized.

Objective 1: Describe patient-related and hospice-related characteristics such as gender,
average length of hospice service, primary diagnoses, average daily census, number of
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admissions per year, net operating revenues, inpatient unit (IPU) operating costs and
pharmacy costs.
Five statistical reports provided by the five hospices for year 2007 were utilized to
achieve this objective. A mean for each of the patient-related and hospice-related
characteristics was calculated from the five statistical reports obtained from the five
hospices in Ohio.

Objective 2: Compare patient-related and hospice-related characteristics of the five
hospices in Ohio with NHPCO data.
For this objective, statistical reports from the five hospices as well as the annual reports
of NHPCO for year 2007 were used. The mean or average for the characteristics obtained
from objective 1 was used to compare with NHPCO data. The characteristics that were
compared were gender, average length of hospice service (LOS), primary diagnoses,
average daily census, and total patient days.

Objective 3: Identify therapeutic drug classes and medications with the most frequent
utilization rates and largest percentage of expenditures in hospice care.
A) For combined dataset
Combined PBM claims dataset from all study hospices was used to achieve this
objective. Descriptive analyses were conducted to identify ten therapeutic classes based
on Rx count and total cost. The frequencies (sum) of Rx count and sum of the total costs
for medications under each therapeutic class were computed. The ten therapeutic classes
with highest Rx count and ten therapeutic classes with highest total cost were reported.
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Similar statistics were conducted to identify ten medications based on Rx Count and total
cost and results were reported.
B) For individual hospice data
Individual hospice data for hospice 1, hospice 2, hospice 3, hospice 4, and hospice 5 were
used for this objective. Descriptive analyses, similar to objective for combined dataset
were conducted to identify five therapeutic classes and five medications based on Rx
count and total cost for each of the hospice.

Objective 4: Further analyze medication costs and utilization rates under the identified
therapeutic class of medications.
Descriptive analyses were conducted to find frequencies (sum) of Rx count and total cost
for each medication under each of the ten different identified therapeutic classes. Five
medications whose frequency of use contributes to largest expenditures under the
identified therapeutic classes were reported.

The next chapter will discuss the results obtained by making use of the data and
methodology.
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CHAPTER 4
RESULTS

Previous chapters provided an overview of hospice care, outlined the specific
study objectives, discussed some studies that have analyzed hospice characteristics and
medication utilization in hospices, and described the study methodology and data
sources. This chapter presents the results for each of the study objectives.

Individual PBM data from the Ohio hospices were employed to analyze
therapeutic classes and medication utilization. Combined dataset from all five hospices
were analyzed to study the overall medication utilization among these hospices. This
combined dataset consisted of 1,020 different drug names under 246 therapeutic classes.

For the study objective 1, statistical reports obtained from five hospices in Ohio
for year 2007 were evaluated; while for objective 2, both statistical reports from five
Ohio hospices and NHPCO reports were evaluated.

Objective 1: Frequency of Patient- and Hospice-related Characteristics
An average for all the patient- and hospice-related characteristics included in the
statistical reports of study hospices in Ohio was calculated for the year 2007. Patient
characteristics included gender, average length of hospice service, and primary diagnoses.
Hospice-related characteristics included number of admissions per year, average daily
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census, net operating revenues, inpatient unit [IPU] operating costs and pharmacy costs.

Patient-related Characteristics
There were approximately equal numbers of male (50.6%) and female hospice
patients (49.4%). Mean length of stay (LOS) for year 2007 was 73.6 days, while median
length of stay was 20.8 days among these hospices. Average number of patients with noncancer diagnosis (58.5%) was higher than those with cancer. Majority of patients referred
to a hospice had a terminal diagnosis from cancer, heart diseases, lung diseases, stroke or
coma and Dementia or Alzheimer’s disease (Refer Table 1).

Hospice-related Characteristics
The average number of admissions for the five hospices was 627 patients for year
2007. Average daily census was 136 patients and total patient days averaged 51,350 days
in these five hospices. Net operating revenues for the study hospices ranged from a
minimum of $500,000 to $13.8 million per hospice. The major components of expenses
identified in the hospices were annual physician salary costs, annual nursing salary costs,
inpatient unit (IPU) operating costs, durable medical equipment (DME) costs, pharmacy
costs and bereavement costs.

For year 2007, average annual physician salary in each hospice was calculated to
be $87,500. Around $930,000 was the average nursing staff salary costs, while vast
differences in bereavement costs per hospice was observed. Average bereavement costs
ranged from $4,500 to $222,000 per hospice. Durable medical equipment (DME) costs
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varied from $170,000 to $600,000 per hospice, while the inpatient unit (IPU) operating
costs varied from $700,000 to $1.7 million per hospice (Refer Table 2).

A total of 59,174 prescription claims among the five hospices accounted for
approximately $1.85 million worth of medications. Annual drug expenditures for each
hospice averaged $371,750 and an average hospice medication cost per patient per day
(PPPD) was $11.12 ($12.43 PPPD for home care and $8.5 PPPD for nursing care) for
year 2007. With the exclusion of outliers such as enoxaparin injections, average hospice
medication cost was $10.72 PPPD.
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Table 1. Patient characteristics in five hospices of Ohio for year 2007

Patient Characteristics

N%

Gender
Male

50.6

Female

49.4

Length of Service (LOS)
Mean LOS
Median LOS

73.6
20.8

Primary Diagnoses
Cancer

41.5

Non-Cancer

58.5
Heart Diseases

10.2

Liver Diseases

8.8

Lung Diseases

7.2

Kidney Diseases

5.4

HIV/AIDS

0.2

Stroke/Coma

3.3

ALS

2.3

Other Motorneuron

2.8

Debility Unspecified

11.2

Other

7

N% = percentage of frequency.
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Table 2. Characteristics of five hospices in Ohio for year 2007
Characteristic

Mean

Range

Number of admissions

627 patients

461 to 1,059 patients

Daily census

136 patients

79 to 250 patients

Total patient days

51,350 days

28,743 to 91,355 days

Net operating revenues

$7.5 million

$500,000 to $13.8 million

Physician salary

$87,500

$83,748 to $263,000

Collective Nursing salary

$930,000

$867,723 to $1.1 million

Bereavement costs

$75,875

$4,500 to $222,000

DME costs

$237,500

$170,000 to $600,000

IPU costs

$980,000

$700,000 to $1.7million

Annual drug costs

$371,750

$67,580 to $ 763,413

N= Sum of frequencies; DME= Durable Medical Equipment; IPU=Inpatient Unit
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Objective 2. Compare patient- and hospice-related characteristics of the five Ohio
hospices with 2007 NHPCO data.
Statistical reports obtained from the five hospices were compared to the annual
reports of NHPCO for year 2007. An average for patient and hospice characteristics was
computed (objective 1) and compared with NHPCO data. The characteristics that were
compared included average length of hospice service (LOS), primary diagnoses, gender,
average daily census, and total patient days.
The average daily census (136 patients) and total patient days (51,350 days) in
five study hospices were, approximately, 1.5 times higher as compared to that of NHPCO
data (90 patients and 31,300 days, respectively). Number of males (50.6%) and mean
length of service (73.6 days) were slightly greater than those seen in the NHPCO data
(46.1% and 67.4 days, respectively). Similar to NHPCO data (55.1%), number of patients
with non-cancer diagnosis (58.5%) was found to be higher than those with cancer in these
hospices.
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Table 3. Comparison of Ohio hospice data to NHPCO data.
Characteristics

Ohio hospice data

NHPCO data

Average. daily census

136 patients

90 patients

Total patient days

51,350 days

31,300 days

Males

50.60%

46.10%

Females

49.40%

53.90%

LOS

73.6 days

67.4 days

Cancer

41.50%

44.90%

Non-cancer

58.50%

55.10%

Gender

Primary diagnoses

LOS = Length of stay
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Objective 3: To identify ten therapeutic drug classes with most frequent utilization
rates and largest percentage of expenditure in hospice care and analyze five most
frequently utilized therapeutic classes.
A) For combined dataset
Ten therapeutic drug classes with most frequent utilization rates and largest
percentage of expenditure in hospice care
Approximately 1,020 different drugs under 246 therapeutic classes were utilized in the
five hospices. Descriptive analyses for therapeutic class sorted by Rx Count were
conducted to find the frequencies for prescription count for medications. The sum of
prescription counts for medications under each therapeutic classes were calculated. Ten
therapeutic classes with highest frequency of prescription count were reported. The most
frequently utilized therapeutic class of drugs, based on prescription drug volume (Rx
Count) included analgesic-narcotics (16.3%) followed by laxatives-cathartics (7.9%), and
anti-anxiety drugs (7.2%), glucocorticoids (4.3%), selective serotonin reuptake inhibitors
(SSRIs) (3.8%), loop diuretics (3.7%), gastric acid secretion reducers (3.4%),
antipsychotics - dopamine antagonists, butyrophenones (2.6%), anti-convulsants (2.3%),
and alpha-2-receptor antagonist depressants (1.9%). Out of 246 therapeutics classes,
these ten therapeutic classes are most frequently utilized in Ohio hospices and account for
over 50% of entire prescription volume for year 2007 (refer Table 4).
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Table 4. Ten therapeutic classes sorted by prescription (Rx) count (combined
dataset)

Rx Count

Total Cost

Percentage
%

ANALGESICS,NARCOTICS

9,776

$315,926

16.35%

LAXATIVES AND CATHARTICS

4,730

$43,730

7.91%

ANTI-ANXIETY DRUGS

4,312

$86,690

7.21%

GLUCOCORTICOIDS

2,612

$49,888

4.37%

SELECTIVE SEROTONIN
REUPTAKE INHIBITOR (SSRIS)

2,305

$89,497

3.86%

LOOP DIURETICS
GASTRIC ACID SECRETION
REDUCERS
ANTIPSYCHOTICS,DOPAMINE
ANTAGONISTS,
BUTYROPHENONES

2,260

$14,522

3.78%

2,040

$69,039

3.41%

1,610

$24,092

2.69%

ANTICONVULSANTS
ALPHA-2 RECEPTOR
ANTAGONIST
ANTIDEPRESSANTS

1,354

$67,226

2.26%

1,172

$38,033

1.96%

Grand Total

32,171

$798,642

53.81%

Therapeutic Class

Percentage (%) based on Total Rx Count..

57

Similar analyses for therapeutic classes sorted by total costs in descending order
were conducted to find the costs that were contributed by each therapeutic class. Top ten
therapeutic classes that contributed to majority of drug expenditures were reported. These
included several most frequently utilized therapeutic classes such as analgesics-narcotics
(17%), selective serotonin reuptake inhibitor-SSRIs (4.8%), and anti-anxiety drugs
(4.6%), gastric acid secretion reducers (3.7%), anticonvulsants (3.6%),and
glucocorticoids (2.7%). A few therapeutic classes that were not frequently utilized but
contributed to majority of the expenses included anti-psychotics - dopamine antagonists
(5.2%), beta adrenergic and anticholinergic combinations (3.3%), heparin and related
preparations (3.2%), antiemetic/antivertigo (2.7%).
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Table 5. Ten therapeutic classes sorted by total cost (combined dataset)

Therapeutic Class

Rx
Count

Total Cost

Percentage
%

ANALGESICS,NARCOTICS

9,776

$315,926

17.00%

802

$96,023

5.17%

2,305

$89,497

4.81%

ANTI-ANXIETY DRUGS
GASTRIC ACID SECRETION
REDUCERS

4,312

$86,690

4.66%

2,040

$69,039

3.71%

ANTICONVULSANTS
BETA-ADRENERGIC AND
ANTICHOLINERGIC
COMBINATIONS
HEPARIN AND RELATED
PREPARATIONS

1,354

$67,226

3.62%

468

$61,087

3.29%

99

$58,533

3.15%

GLUCOCORTICOIDS
ANTIEMETIC/ANTIVERTIGO
AGENTS

2,612

$49,888

2.68%

698

$49,250

2.65%

Grand Total

24,466

$943,159

50.74%

ANTIPSYCHOTICS,ATYPICAL,DOP
AMINE,& SEROTONIN
ANTAGONIST
SELECTIVE SEROTONIN
REUPTAKE INHIBITOR (SSRIS)

Percentage (%) based on total costs.
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Further, five most utilized therapeutic classes were analyzed to identify
medications whose frequency of use contributed to majority of the expenses. Under
therapeutic class analgesics-narcotics, medications such as morphine sulphate (31.7% utilization, 25.2%- expenses), methadone (18.9% - utilization, but contributed to only
5.1% of entire analgesic-narcotics expenditure), oxycodone (11.4%, 20.3%),
hydrocodone - acetaminophen (9%, 3.9%), and Eth- Oxydose (7%, 10.1%) were most
frequently utilized and contributed to majority of expenditures. Fentanyl, whose
frequency of use was only 5.9% of analgesic-narcotics class, contributed to 21.5% of
expenditure.

Under therapeutic class laxatives-cathartics, the medications with most frequent
utilization were senna S (34.9%), senna plus (11.4%), docusate sodium (10.4%), milk of
magnesia (6.9%) and senna (5.9%). These five medications contributed to approximately
70% of laxatives-cathartics utilization in the hospices. Under anti-anxiety medication
class, the medications that were most frequently utilized and contributed to majority of
expenses included lorazepam (60.3%, 64.6%), alprazolam (29.8%, 15.8%), lorazepam
intensol (6.3%, 14.1%), diazepam (2%, 1.5%), and busiprone (1%, 0.8%); these
medications contributed to over 95% of utilization and expenditure of anti-anxiety class.
Similarly, under SSRIs, the medications were sertraline (40.1%, 44.0%), citlaopram
(20.6%, 6.9%), paroxetine (17.2%, 19.7%), escitalopram (17%, 22%), and fluoxetine
(3%, 3%). Under therapeutic class glucocorticoids, the medications contributing to most
frequent utilization and expenditure were prednisone (67.9%, 18.1%), dexamethasone
(22.7%, 26.4%), budesonide (3.5%, 38.1%), methylprednisolone (1, 8.1%), and
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dexamethasone sodium phosphate (1, 0.4%). (Refer Tables 6, 7, 8, 9, 10, 11).
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Table 6. Medications contributing to most frequent utilization and majority of
expenditure under therapeutic class analgesics-narcotics.
Therapeutic
Class
ANALGESICS,
NARCOTICS

Percentage Percentage
(%) Rx
(%) Total
Count
Cost

Rx
Count

Total Cost

3,114

$80,489

31.85%

25.48%

OXYCODONE

1,133

$67,893

11.59%

21.49%

FENTANYL
ETHOXYDOSE

548

$64,664

5.61%

20.47%

659

$30,953

6.74%

9.80%

1,941

$17,074

19.85%

5.40%

9,776

$315,926

16.35%

17.00%

Drug Name
MORPHINE
SULFATE

METHADONE
ANALGESICS, NARCOTICS
Total

Table 7. Medications contributing to most frequent utilization and majority of
expenditure under therapeutic class laxatives-cathartics.
Therapeutic
Class
Drug Name
LAXATIVES
AND
SENNA S
CATHARTICS
SENNA PLUS
DOCUSATE
SODIUM
MILK OF
MAGNESIA
SENNA
LAXATIVES AND
CATHARTICS Total

Percentage Percentage
(%) Rx
(%) Total
Count
Cost

Rx
Count

Total Cost

1,655

$15,438

34.99%

35.30%

538

$5,983

11.37%

13.68%

492

$2,890

10.40%

6.61%

326

$2,159

6.89%

4.94%

281

$2,252

5.94%

5.15%

4,730

$43,730

7.91%

2.35%
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Table 8. Medications contributing to most frequent utilization and majority of
expenditure under therapeutic class anti-anxiety drugs.
Therapeutic
Class
ANTIANXIETY
DRUGS

Percentage Percentage
(%) Rx
(%) Total
Count
Cost

Drug Name

Rx
Count

Total
Cost

LORAZEPAM

2,577

$55,929

59.76%

64.52%

ALPRAZOLAM
LORAZEPAM
INTENSOL

1,284

$13,512

29.78%

15.59%

290

$13,012

6.73%

15.01%

DIAZEPAM

88

$1,343

2.04%

1.55%

BUSPIRONE HCL

39

$761

0.90%

0.88%

4,312

$86,690

7.21%

4.66%

ANTI-ANXIETY DRUGS Total

Table 9. Medications contributing to most frequent utilization and majority of
expenditure under therapeutic class SSRIs.
Therapeutic
Class
SELECTIVE
SEROTONIN
REUPTAKE
INHIBITOR
(SSRIS)

Percentage Percentage
(%) Rx
(%) Total
Count
Cost

Drug Name

Rx
Count

Total
Cost

SERTRALINE

926

$39,337

40.17%

43.95%

CITALOPRAM

468

$6,070

20.30%

6.78%

PAROXETINE

411

$18,014

17.83%

20.13%

ESCITALOPRAM

382

$19,781

16.57%

22.10%

FLUOXETINE

69

$2,557

2.99%

2.86%

2,305

$89,497

3.86%

4.81%

(SSRIS) Total
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Table 10. Medications contributing to most frequent utilization and majority of
expenditure under therapeutic class glucocorticoids.
Therapeutic
Class
GLUCOCOR
TICOIDS

Percentage Percentage
(%) Rx
(%) Total
Count
Cost

Rx
Count

Total Cost

PREDNISONE
DEXAMETHA
SONE

1,804

$9,321

69.07%

18.68%

620

$14,356

23.74%

28.78%

BUDESONIDE
METHYLPRE
DISOLONE
METHYLPRE
DNISOLONE

90

$18,859

3.45%

37.80%

23

$4,011

0.88%

8.04%

14

$458

0.54%

0.92%

2,612

$49,888

4.37%

2.68%

Drug Name

GLUCOCORTICOIDS Total

Table 11. Medications contributing to most frequent utilization and majority of
expenditure under therapeutic class antipsychotics, atypical, dopamine & serotonin
anatagonist.
Therapeutic
Class
ANTIPSYCHOT
ICS,
ATYPICAL,
DOPAMINE &
SEROTONIN
ANTAGONIST

Percentage Percentage
(%) Rx
(%) Total
Count
Cost

Drug Name

Rx
Count

Total
Cost

QUETIAPINE

380

$38,780

47.38%

40.39%

RISPERDAL

303

$34,631

37.78%

36.07%

ZYPREXA

81

$16,208

10.10%

16.88%

25

$2,431

3.12%

2.53%

7

$2,411

0.87%

2.51%

802

$96,023

1.34%

5.17%

ZIPRASIDONE
RISPERDAL
CONSTA
ANTIPSYCHOTICS,ATYPICAL
,DOPAMINE,& SEROTONIN
ANTAG Total
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Objective 3: To identify five therapeutic drug classes with most frequent utilization
rates and largest percentage of expenditure in hospice care and analyze five most
frequently utilized therapeutic classes.
B) For individual hospice dataset
Descriptive analyses were run using individual hospice data to identify five therapeutic
classes and medications that were most frequently utilized and contributing to majority of
expenditure within each hospice.
For Hospice 1
Approximately 236 medications categorized under 105 therapeutic classes were
utilized in hospice 1.
Therapeutic drug classes with most frequent utilization rates and largest percentage of
expenditure in hospice care.
For this objective, claims data for hospice 1 were utilized. Descriptive analysis were
conducted to identify most utilized therapeutic classes revealed that analgesics-narcotics
(22.3%), laxatives-cathartics (11.5%), anti-anxiety drugs (7.3%), glucocorticoids (4.9%),
and loop diuretics (3.5%) were the five most utilized therapeutic drug classes in hospice
1. These results were found to be consistent with the results obtained using the combined
dataset. When analyzed to identify therapeutic classes contributing to largest percentage
of expenditure, analgesics-narcotics, anti-anxiety drugs, selective serotonin reuptake
inhibitors (SSRIs), beta-adrenergic and glucocorticoid combination and anticonvulsants
were found as drug classes contributing to majority of expenditure in hospice 1. (Refer
Table 12 &13)
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Table 12. Therapeutic classes most frequently utilized in hospice 1.

Therapeutic Class

Rx Count

Total Cost

Percentage (%)

ANALGESICS, NARCOTICS

554

$17,747

22.32%

LAXATIVES AND CATHARTICS

286

$2,579

11.52%

ANTI-ANXIETY DRUGS

182

$5,089

7.33%

GLUCOCORTICOIDS

121

$1,762

4.88%

LOOP DIURETICS

86

$655

3.46%

1,229

$27,832

49.52%

Grand Total
Percentage (%) based on Rx Count

Table 13.Therapeutic classes contributing to largest percentage of expenditure in
hospice 1.
Therapeutic Class

Rx Count

Total Cost

Percentage (%)

ANALGESICS,NARCOTICS

554

$17,747

26.26%

ANTI-ANXIETY DRUGS

182

$5,089

7.53%

SELECTIVE SEROTONIN
REUPTAKE INHIBITOR (SSRIS)

80

$3,561

5.27%

BETA-ADRENERGIC AND
GLUCOCORTICOID
COMBINATIONS

13

$3,231

4.78%

ANTICONVULSANTS

39

$2,932

4.34%

Grand Total

868

$32,560

48.18%

Percentage (%) based on Total Cost.
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For Hospice 2
Therapeutic drug classes with most frequent utilization rates and largest percentage of
expenditure in hospice care.
Descriptive analyses for calculating frequency of utilization for therapeutic classes and
those contributing to largest percentage of expenditure were conducted using individual
data for hospice 2. Most utilized therapeutic classes identified in hospice 2 were
analgesics-narcotics (20%), anti-anxiety drugs (10.3%), laxatives-cathartics (8.2%),
glucocorticoids (5%), and SSRIs (4.3%) were the five most utilized therapeutic drug
classes in hospice 1. These results were found to be consistent with the results obtained
using the combined dataset. Therapeutic classes contributing to largest percentage of
expenditure were analgesics-narcotics (20.2%), anti-anxiety drugs (6.6%), selective
serotonin reuptake inhibitors (SSRIs)(5.8%), anticonvulsants (5.1%) and beta-adrenergic
and glucocorticoid combination (4.8%). These results were found to be similar to results
from combined dataset and results of hospice 1. (Refer Tables 14 & 15)
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Table 14. Therapeutic classes most frequently utilized in hospice 2.

Therapeutic Class

Rx
Count

Total Cost

Percentage (%)

ANALGESICS,NARCOTICS

1,493

$36,797

20.00%

ANTI-ANXIETY DRUGS

769

$12,042

10.30%

LAXATIVES AND CATHARTICS

615

$5,786

8.24%

GLUCOCORTICOIDS
SELECTIVE SEROTONIN
REUPTAKE INHIBITOR (SSRIS)

372

$7,864

4.98%

318

$10,512

4.26%

3,567

$73,001

47.78%

Grand Total
Percentage (%) based on Rx Count.

Table 15. Therapeutic classes contributing to majority of expenditure in hospice 2.

Therapeutic Class

Rx
Count

Total Cost

Percentage
(%)

ANALGESICS,NARCOTICS

1,493

$36,797

20.18%

ANTI-ANXIETY DRUGS
SELECTIVE SEROTONIN
REUPTAKE INHIBITOR (SSRIS)

769

$12,042

6.60%

318

$10,512

5.77%

ANTICONVULSANTS

246

$9,332

5.12%

BETA-ADRENERGIC AGENTS

146

$8,392

4.60%

2,972

$77,075

42.27%

Grand Total
Percentage (%) based on Total Cost.
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For Hospice 3
Approximately 558 medications under 182 therapeutic classes were utilized in hospice 3.
Therapeutic drug classes with most frequent utilization rates and largest percentage of
expenditure in hospice care.
Most utilized therapeutic classes identified in hospice 3 included analgesics-narcotics
(15.6%), anti-anxiety drugs (5.7%), laxatives-cathartics (9.7%), glucocorticoids (4.4%),
and gastric acid secretion reducers (4.4%) were the five most utilized therapeutic drug
classes in hospice 1. These results were found to be consistent with the results obtained
using the combined dataset. Therapeutic classes contributing to largest percentage of
expenditure were analgesics-narcotics (16.6%), heparin and related preparations (6.6%),
antipsychotics, atypical, dopamine, & serotonin antagonist (5.8%), gastric acid secretion
reducers (4.4%), and antiemetics/antivertigo agents (4.2%). Unlike results from
combined dataset, therapeutic classes such as heparin and related preparations and
antiemetics/antivertigo agents contribute to a very large percentage of expenditure in
hospice 3. (Refer Tables 16 & 17)
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Table 16. Therapeutic classes most frequently utilized in hospice 3.

Therapeutic Class

Rx
Count

Total Cost

Percentage
(%)

ANALGESICS,NARCOTICS

2,181

$76,044

15.51%

LAXATIVES AND CATHARTICS

1,338

$11,827

9.52%

ANTI-ANXIETY DRUGS

798

$18,509

5.68%

GLUCOCORTICOIDS

615

$8,411

4.37%

GASTRIC ACID SECRETION REDUCERS

610

$20,036

4.34%

5,542

$134,826

39.41%

Grand Total
Percentage (%) based on Rx Count.

Table 17. Therapeutic classes contributing to majority of expenditure in hospice 3.
Therapeutic Class

Rx
Count

Total
Cost

Percentage
(%)

ANALGESICS,NARCOTICS

2,181

$76,044

16.36%

HEPARIN AND RELATED PREPARATIONS

58

$30,252

6.51%

ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,&
SEROTONIN ANTAGONIST

292

$26,361

5.67%

GASTRIC ACID SECRETION REDUCERS

610

$20,036

4.31%

ANTIEMETIC/ANTIVERTIGO AGENTS

231

$19,136

4.12%

3,372

$171,829

36.96%

Grand Total

Percentage(%) based on Total Cost
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For Hospice 4
Approximately 668 medications were utilized under 198 therapeutic drug classes.
Therapeutic drug classes with most frequent utilization rates and largest percentage of
expenditure in hospice care.
Consistent with results obtained from the combined dataset, hospice 1, hospice 2 and
hospice 3, therapeutic classes most frequently utilized and contributing to largest
percentage of expenditure in hospice 4 were analgesics, narcotics (16.7%- utilization,
16.9%-expenditure), anti-anxiety drugs (7.6%, 4.2%), and SSRIs (3.7%, 5%) The classes
that were most frequently utilized but did not contribute significantly to expenditure in
hospice 4 included laxatives and cathartics (4.5%), and loop diuretics (4%). Therapeutic
classes that contributed to majority of expenditure in hospice 4, but were not the most
frequently utilized ones included antipsychotics, atypical, dopamine & serotonin
antagonists (5.7%), and beta adrenergic and glucocorticoid combinations (4.2% ). (Table
18 & 19)
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Table 18. Therapeutic classes most frequently utilized in hospice 4.

Therapeutic Class

Rx Count Total Cost

Percentage
(%)

ANALGESICS,NARCOTICS

3,437

$124,290

16.24%

ANTI-ANXIETY DRUGS

1,573

$30,620

7.43%

LAXATIVES AND CATHARTICS

932

$10,150

4.40%

LOOP DIURETICS

820

$6,876

3.87%

SELECTIVE SEROTONIN REUPTAKE
INHIBITOR (SSRIS)

765

$37,058

3.61%

7,527

$208,995

35.57%

Grand Total
Percentage (%) based on Rx Count.

Table 19. Therapeutic classes contributing to majority of expenditure in hospice 4.

Rx Count

Total Cost

Percentage
(%)

ANALGESICS,NARCOTICS

3,437

$124,290

16.28%

ANTIPSYCHOTICS,ATYPICAL,DOPA
MINE,& SEROTONIN ANTAG

289

$41,933

5.49%

765

$37,058

4.85%

183

$31,117

4.08%

ANTI-ANXIETY DRUGS

1,573

$30,620

4.01%

Grand Total

6,247

$265,018

34.71%

Therapeutic Class

SELECTIVE SEROTONIN REUPTAKE
INHIBITOR (SSRIS)
BETA-ADRENERGIC AND
ANTICHOLINERGIC
COMBINATIONS

Percentage (%) based on Total Cost.
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For Hospice 5
Approximately 478 drugs under 168 therapeutic drug classes were utilized in hospice 5.
Therapeutic drug classes with most frequent utilization rates and largest percentage of
expenditure in hospice care.
Drug classes that were highly utilized included analgesics, narcotics (14.5%), laxativescathartics (10.7%), anti-anxiety drugs (7%), glucocorticoids (5.2%), and loop diuretics
(4.3%). These results were almost similar to results obtained earlier from other hospice
data. Therapeutic classes accounting for majority of expenditure were analgesics,
narcotics (16%), heparin and related preparations (6.1%), anti-anxiety drugs (5.4%),
SSRIs (5.2%), and antipsychotics, atypical dopamine, serotonin antagonists (5.1%).
(Refer Tables 20 & 21)
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Table 20. Therapeutic classes most frequently utilized in hospice 5.

Therapeutic Class

Rx
Count

Total
Cost

Percentage
(%)

ANALGESICS,NARCOTICS

2,111

$61,049

14.45%

LAXATIVES AND CATHARTICS

1,559

$13,387

10.67%

ANTI-ANXIETY DRUGS

990

$20,430

6.78%

GLUCOCORTICOIDS

759

$16,130

5.19%

LOOP DIURETICS

631

$3,203

4.32%

6,050

$114,199

41.40%

Grand Total
Percentage (%) based on Rx Count.

Table 21. Therapeutic classes contributing to majority of expenditure in hospice 5.
Rx
Count

Total
Cost

Percentage
(%)

ANALGESICS,NARCOTICS

2,111

$61,049

16.04%

HEPARIN AND RELATED PREPARATIONS

30

$23,110

6.07%

ANTI-ANXIETY DRUGS

990

$20,430

5.37%

SELECTIVE SEROTONIN REUPTAKE
INHIBITOR (SSRIS)

609

$19,864

5.22%

ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,&
SEROTONIN ANTAGONIST

136

$19,443

5.11%

Grand Total

3,876

$143,895

37.81%

Therapeutic Class

Percentage (%) based on Total Cost.
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Objective 4: To identify ten medications with most frequent utilization rates and
largest percentage of expenditure in hospice care.
A) For Combined Dataset
Ten medications with most frequent utilization rates and largest percentage of
expenditure in hospice care.
Medications whose frequency of use accounted for high utilization as well as
expense included morphine sulfate (5.2% - utilization, 4.3% - expenditure) and
lorazepam (4.4%, 3.0 %), while medications such as furosemide (4%, 0.6%), methadone
(3.25%, 0.9%), and prednisone (3.0%, 0.5%) contributed highly to utilization, but were
not a significant contributor to expenditure. There were certain medications such as
enoxaparin injections whose frequency of utilization was low (0.01%), but contributed to
3.1% of total medication expenditure. Likewise, fentanyl and oxycodone contributed to
3.5% and 3.7%, respectively to the total medication expenditure, but their frequency of
utilization was very low, only 0.9% and 1.9%, respectively (Refer Tables 22 and 23).

The listed 10 medications (Table 22) were the most significant contributors to
utilization. They accounted for 31% of entire medication utilization in the hospices. Table
23 lists the top 10 medications contributing significantly to expenditures. Out of the
1,020 medications, the listed medications contributed to about 27.5% of total
expenditure.
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Table 22. Ten medications sorted by prescription (Rx) count (combined dataset)

Drug Name

Rx Count

Total Cost

Percentage %

MORPHINE SULFATE

3,114

$80,489

5.21%

LORAZEPAM

2,606

$56,552

4.36%

FUROSEMIDE

2,148

$10,949

3.59%

METHADONE

1,941

$17,074

3.25%

PREDNISONE

1,804

$9,321

3.02%

SENNA S

1,655

$15,438

2.77%

HALOPERIDOL

1,466

$21,225

2.45%

ALPRAZOLAM

1,284

$13,512

2.15%

MIRTAZAPINE

1,171

$38,026

1.96%

OXYCODONE HCL

1,133

$67,893

1.90%

Grand Total

18,322

$330,481

30.65%

Percentage (%) based on total Rx Count.
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Table 23. Ten medications sorted by total costs. (Combined dataset)

Drug Name

Rx Count

Total Cost

Percentage %

MORPHINE SULFATE

3,114

$80,489

4.33%

OXYCODONE

1,133

$67,893

3.65%

FENTANYL

548

$64,664

3.48%

LORAZEPAM

2,606

$56,552

3.04%

ENOXAPARIN INJECTIONS

63

$56,511

3.04%

SERTRALINE

926

$39,337

2.12%

QUETIAPINE

380

$38,780

2.09%

MIRTAZAPINE

1,171

$38,026

2.05%

RISPERDAL

303

$34,631

1.86%

OXYCODONE

659

$30,953

1.67%

Grand Total

10,903

$507,836

27.32%

% percentage based on total Cost.
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Objective 4: To identify ten medications with most frequent utilization rates and
largest percentage of expenditure in hospice care.
B) For individual hospice dataset
Descriptive analyses were run using individual hospice data to identify five therapeutic
classes and medications that were most frequently utilized and contributing to majority of
expenditure within each hospice
For Hospice 1
Medications with most frequent utilization rates and largest percentage of expenditure
in hospice care.
Medications that were most frequently utilized and contributed to largest percentage of
expenditure in hospice 1 included methadone (7.6%-utilization, 2.8%-expenditure),
morphine sulfate (7.2%, 7%), lorazepam (3.4%, 3.7%), and oxycodone (3.1%, 10%).
Furosemide (3.1%) was also found to be frequently utilized, but contributed to only about
0.6% of expenditure; while fluticasone propionate (4.8%) contributed to a large
percentage of expenditure. (Refer Tables 24 & 25)

These listed medications in tables 24 & 25 alone contributed to 27.5% of
utilization & 25% of total medication expenditure in hospice 1.
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Table 24. Medications most frequently utilized in hospice 1.

Drug Name

Rx Count

Total Cost

Percentage (%)

METHADONE

189

$1,873

7.61%

MORPHINE SULFATE

179

$4,737

7.21%

LORAZEPAM

84

$2,500

3.38%

FUROSEMIDE

78

$393

3.14%

OXYCODONE

76

$6,784

3.06%

Grand Total

682

$16,762

27.48%

Percentage (%) based on Rx Count

Table 25. Medications contributing to majority of expenditure in hospice 1.

Drug Name

Rx Count

Total Cost

Percentage (%)

OXYCODONE

76

$6,784

10.04%

MORPHINE SULFATE

179

$4,737

7.01%

FLUTICASONE PROPIONATE

13

$3,231

4.78%

LORAZEPAM

84

$2,500

3.70%

METHADONE

189

$1,873

2.77%

Grand Total

541

$19,126

28.30%

Percentage (%) based on Total Cost.
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For Hospice 2
Medications with most frequent utilization rates and largest percentage of expenditure
in hospice care.
Medications, whose frequency of use contributed to majority of expenditure in hospice 2
included lorazepam (9.1%-utilization, 5.9%-expenditure) and morphine sulphate (8.9%,
6.4%). Other medications most frequently utilized included senna S (4%), prednisone
(3.3%), haloperidol (2.9%); and medications that contributed to majority of expenditure
included fentanyl (5.9%), oxycodone (2.8%) and sertraline (2.8%). (Refer Tables 26 &
27).
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Table 26. Medications most frequently utilized in hospice 2.

Drug Name

Rx Count

Total Cost

Percentage (%)

LORAZEPAM

681

$10,763

9.12%

MORPHINE SULFATE

663

$11,742

8.88%

SENNA S

301

$2,611

4.03%

PREDNISONE

250

$1,179

3.35%

HALOPERIDOL

213

$2,781

2.85%

2,108

$29,076

28.24%

Grand Total
Percentage (%) based on Rx Count.

Table 27. Medications contributing to majority of expenditures in hospice 2.

Drug Name

Rx Count

Total Cost

Percentage (%)

MORPHINE SULFATE

663

$11,742

6.44%

FENTANYL

89

$10,777

5.91%

LORAZEPAM

681

$10,763

5.90%

OXYCODONE

136

$5,060

2.77%

SERTRALINE

155

$5,052

2.77%

1,724

$43,393

23.80%

Grand Total
Percentage (%) based on Total Cost.
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For Hospice 3
Medications with most frequent utilization rates and largest percentage of expenditure
in hospice care.
Morphine sulphate was most frequently utilized and contributed to significant
expenditure. Medications that were highly utilized in hospice 3 included furosemide
(3.9%), lorazepam (3.8%), senna S (3.1%), and methadone HCl (2.6%). Medications that
accounted to large expenditures included enoxaparin injections (6.5%), fentanyl (5.5%),
risperdal (2.9%), and oxycodone (2.8%). (Refer Tables 28 & 29)
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Table 28. Medications most frequently utilized in hospice 3.

Drug Name

Rx Count

Total Cost

Percentage (%)

MORPHINE SULFATE

813

$21,981

5.78%

FUROSEMIDE

541

$2,644

3.85%

LORAZEPAM

537

$10,328

3.82%

SENNA S

434

$3,878

3.09%

METHADONE

360

$2,929

2.56%

2,685

$41,760

19.10%

Grand Total
Percentage (%) based on Rx Count.

Table 29 . Medications contributing to majority of expenditure in hospice 3.

Drug Name

Rx Count

Total Cost

Percentage (%)

ENOXAPARIN INJECTIONS

28

$29,889

6.43%

FENTANYL

228

$24,962

5.37%

MORPHINE SULFATE

813

$21,981

4.73%

RISPERDAL

117

$13,420

2.89%

OXYCODONE

225

$12,939

2.78%

1,411

$103,191

22.20%

Grand Total
Percentage (%) based on Total Cost.
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For Hospice 4
Medications with most frequent utilization rates and largest percentage of expenditure
in hospice care.
Morphine sulphate was the most utilized medication (4.8%) that contributed to the largest
percentage of expenditure (4.1%) in hospice 4; while lorazepam contributed to 2.5% of
expenditures with 3.4% of utilization rate. Other most utilized medications were
alprazolam (3.7%), furosemide (3.6%), and methadone (3.3%); and medications with
largest percentage of expenditure included fentanyl (3.2%), oxycodone (3%), sertraline
HCl (2.4%). (Refer tables 30 & 31)
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Table 30. Medications most frequently utilized in hospice 4.

Drug Name

Rx Count

Total Cost

Percentage (%)

MORPHINE SULFATE

990

$29,795

4.68%

ALPRAZOLAM

760

$8,131

3.59%

FUROSEMIDE

745

$4,042

3.52%

LORAZEPAM

693

$18,040

3.27%

METHADONE

674

$6,973

3.18%

3,862

$66,981

18.25%

Grand Total
Percentage (%) based on Rx Count.

Table 31. Medications contributing to majority of expenditures in hospice 4.

Drug Name

Rx Count

Total Cost

Percentage (%)

MORPHINE SULFATE

990

$29,795

3.90%

FENTANYL

172

$23,687

3.10%

OXYCODONE

262

$22,073

2.89%

LORAZEPAM

693

$18,040

2.36%

SERTRALINE

351

$17,586

2.30%

3,025

$140,336

18.38%

Grand Total
Percentage (%) based on Total Cost.
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For Hospice 5
Medications with most frequent utilization rates and largest percentage of expenditure
in hospice care.
Lorazepam was the medication whose frequency of use contributed to majority of
expenditure (4.2%-utilization, 3.9%-expenditure). Senna S (5%), furosemide (4.3%),
prednisone (3.9%), and methadone (3.7%) were the medications that were most
frequently utilized in hospice 5. Medications that contributed to largest percentage of
expenditure included oxycodone (6%), enoxaparin injections (5.7%), mirtazapine (3%),
morphine sulphate (3.2%). (Refer Tables 32 & 33)
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Table 32. Medications most frequently utilized in hospice 5.

Drug Name

Rx Count

Total Cost

Percentage (%)

SENNA S

723

$5,943

4.95%

FUROSEMIDE

630

$3,171

4.31%

LORAZEPAM

611

$14,921

4.18%

PREDNISONE

564

$2,868

3.86%

METHADONE

546

$4,055

3.74%

3,074

$30,958

21.04%

Grand Total
Percentage (%) based on Rx Count.

Table 33. Medications contributing to majority of expenditures in hospice 5.

Drug Name

Rx Count

Total Cost

Percentage (%)

OXYCODONE
ENOXAPARIN
INJECTIONS

462

$22,967

6.04%

29

$21,569

5.67%

LORAZEPAM

611

$14,921

3.92%

MORPHINE SULFATE

469

$12,235

3.22%

MIRTAZAPINE

373

$11,231

2.95%

1,944

$82,923

21.79%

Grand Total
Percentage (%) based on Total Cost.
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Finally, analyses were conducted to find percentage of therapeutic class and
medication utilization by each hospice. Descriptive analysis suggested that analgesicsnarcotics was most frequently utilized by hospice 4 (35.2% of the overall analgesicnarcotic utilization by all five hospices), followed by hospice 3 (22.3%) and hospice
5(21.6%). Therapeutic class laxatives-cathartics was most frequently utilized by hospice
5 (33%), hospice 3 (28.3%), and by hospice 4 (19.7%); while anti-anxiety drugs were
highly utilized by hospice 4 (36.5%), hospice 5 (23%), hospice3 (18.5%) and hospice 2
(17.2%). Glucocorticoids were found to be utilized most frequently in hospice 5 (29.1%),
hospice 4 (28.5%) and hospice 3 (27.5%). Hospice 4 (33.2%, 36.3%, 38.7%, 34.5%),
followed by hospice 5 (26.4%, 27.9%, 27.1%, 31.8%) and hospice 3 (23.1%, 25.2%,
16.2%, 19.6%) were found to most frequently utilize therapeutic classes such as SSRIs,
loop diuretics, antipsychotics - dopamine antagonists - butyrophenones, and alpha-2
receptor antagonist antidepressants, respectively. Gastric acid secretion reducers were
most frequently utilized by hospice 3, followed hospice 5 and hospice 4. Anticonvulsants
were frequently utilized by hospice 4, hospice 3 and hospice 5. (Refer Table 34-A)

For medication utilization, hospice 5 utilized majority of oxycodone (40.8%).
Hospice 4 had the highest frequency of utilization for morphine sulphate (31.8%),
methadone HCl (34.7%), alprazolam (59.19%), haloperidol (40.65%), methadone
(34.72%), and mirtazapine (34.5%). (Refer Table 34-B)
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Table 34-A. Therapeutic class utilization by Ohio hospices
Hospice 1

Hospice 2

Hospice 3

Hospice 4

Hospice 5

Rx Count

(%)

Rx
Count

(%)

Rx
Count

(%)

Rx
Count

(%)

Rx
Count

(%)

Total

ANALGESICS, NARCOTICS

554

5.67%

1,493

15.27%

2,181

22.31%

3,437

35.16%

2,111

21.59%

9,776

LAXATIVES AND CATHARTICS

286

6.05%

615

13.00%

1,338

28.29%

932

19.70%

1,559

32.96%

4,730

ANTI-ANXIETY DRUGS

182

4.22%

769

17.83%

798

18.51%

1,573

36.48%

990

22.96%

4,312

GLUCOCORTICOIDS

121

4.63%

372

14.24%

615

23.55%

745

28.52%

759

29.06%

2,612

SELECTIVE SEROTONIN
REUPTAKE INHIBITOR (SSRIS)

80

3.47%

318

13.80%

533

23.12%

765

33.19%

609

26.42%

2,305

LOOP DIURETICS

86

3.81%

154

6.81%

569

25.18%

820

36.28%

631

27.92%

2,260

48

2.35%

251

12.30%

610

29.90%

551

27.01%

580

28.43%

2,040

71

4.41%

219

13.60%

261

16.21%

623

38.70%

436

27.08%

1,610

ANTICONVULSANTS

39

2.88%

246

18.17%

319

23.56%

472

34.86%

278

20.53%

1,354

ALPHA-2 RECEPTOR
ANTAGONIST
ANTIDEPRESSANTS

29

2.47%

136

11.60%

230

19.62%

404

34.47%

373

31.83%

1,172

1,496

4.65%

4,573

14.21%

7,454

23.17%

10,322

32.08%

8,326

25.88%

32,171

Therapeutic Class
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GASTRIC ACID SECRETION
REDUCERS
ANTIPSYCHOTICS,DOPAMINE
ANTAGONISTS,BUTYROPHENO
NES

Grand Total

Percentage (%) based on Rx Count.

Table 34-B. Therapeutic class utilization by Ohio hospices
Hospice 1

Hospice 2

Hospice 3

Hospice 4

Hospice 5

Rx
Count

(%)

Rx
Count

(%)

Rx
Count

(%)

Rx
Count

(%)

Rx
Count

(%)

Total

MORPHINE SULFATE

179

5.75%

663

21.29%

813

26.11%

990

31.79%

469

15.06%

3,114

LORAZEPAM

84

3.22%

681

26.13%

537

20.61%

693

26.59%

611

23.45%

2,606

FUROSEMIDE

78

3.63%

154

7.17%

541

25.19%

745

34.68%

630

29.33%

2,148

189

9.74%

172

8.86%

360

18.55%

674

34.72%

546

28.13%

1,941

PREDNISONE

71

3.94%

250

13.86%

356

19.73%

563

31.21%

564

31.26%

1,804

SENNA S

17

1.03%

301

18.19%

434

26.22%

180

10.88%

723

43.69%

1,655

HALOPERIDOL

54

3.68%

213

14.53%

233

15.89%

596

40.65%

370

25.24%

1,466

ALPRAZOLAM

49

3.82%

69

5.37%

82

6.39%

760

59.19%

324

25.23%

1,284

MIRTAZAPINE

29

2.48%

135

11.53%

230

19.64%

404

34.50%

373

31.85%

1,171

OXYCODONE

76

6.71%

108

9.53%

225

19.86%

262

23.12%

462

40.78%

1,133

Grand Total

826

4.51%

2,746

14.99%

3,811

20.80%

5,867

32.02%

5,072

27.68%

18,322

Therapeutic Class

METHADONE
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Percentage (%) based on Rx Count.

Further, the PPPD medication costs of study hospices were compared with
nationwide hospices for benchmarking purposes. The PPPD medication costs for
nationwide hospices were found from Milliman study(1998) and PoPCRN study(2001)
(Refer Table 36). The costs from these studies were inflated to year 2007 costs for
appropriate comparison. For inflating the costs from earlier years, medical cost inflation
rate from year 1998 -2007 were obtained from United States Bureau of Labor Statistics. A
cumulative inflation rate for these years was computed, which was found to be 42.3%
(Refer Table 35). The 1998 and 2001 year costs were inflated to 2007 year costs using the
following formula:
∑ Inflation Rate = (P0 – P-1)/ P-1*100
where;
P0 = Price/Cost of goods in present year;
P-1 = Price/Cost of goods in the earlier year;
∑ Inflation Rate = Cumulative inflation rate.

For calculating the average PPPD medication costs in study hospices, total costs
for medications per day was divided by number of patients. It was found that certain
medications such as enoxaparin acted as outliers, whose utilization was minimal, but
contributed to over 3% of total medication expenditues. Such outliers were excluded in
the calculation of PPPD. On comparing these inflated costs to the costs from study
hospices, it was found that costs of PPPD medication cost ($10.72 – with the exclusion of
outlier) in study hospices was significantly lower than inflated PPPD medication costs of
Milliman study ($22.1) and PoPCRN study ($14.7) (Refer Table 35).
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Table 35. Medical cost inflation rates. Source: U.S Beareau of Labor Statistics.
Medical Cost

Cumulative Medical Cost Inflation

Year

Inflation Rate

Rate

1998

3.20%

3.20%

1999

3.50%

6.70%

2000

4.10%

10.80%

2001

4.60%

15.40%

2002

4.70%

20.10%

2003

4.00%

24.10%

2004

4.80%

28.50%

2005

4.40%

32.70%

2006

4.20%

36.70%

2007

4.80%

42.30%

1998-2007

42.30%
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Table 36. Comparison of medication costs (PPPD)
PoPCRN
Study
2001

Study Hospices

Original Year

Milliman
Study
1998

PPPD for Original Years

$15.72

$11.47

$10.72

Inflated Costs to Year 2007

$22.10

$14.37

$10.72

2007

PPPD=Per Patient Per Day cost; PoPCRN=The Population-based Palliative Care Research Network.
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CHAPTER 5
DISCUSSION AND CONCLUSIONS

This chapter discusses the findings of this study, draws conclusions, presents
implications, and provides limitations of the study.

This study is an exploratory study and a part of the study analyzed the patient and
hospice related characteristics of the study hospices and compared it with nationwide
hospices using 2007 NHPCO data. The primary focus of this study was to analyze the
medication costs and utilization in hospice care, for which PBM claims data for year
2007 were utilized. It was observed that pharmacy cost is a major component of total
costs of hospice care. Therefore, the study identified some key elements (therapeutic
classes and medications) contributing to significant medication costs produced by hospice
care.

An analysis of reports provided by the five study hospices found that average
number of admissions for the study hospices combined was 627 patients for year 2007.
The average daily census (136 patients) and total patient days (51,350 days) in these five
hospices were 1.5 times higher as compared to that of NHPCO data (90 patients and
31,300 days, respectively). This implies that study hospices were relatively larger sized
hospices. It was also observed that there was equal number of male and female
admissions in 2007; comparing with nationwide hospices using NHPCO data, the number
of male admissions was found to be higher. Similar to NHPCO data (55.1%), number of
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patients with non-cancer diagnosis (58.5%) was higher than those with cancer in these
hospices.

Some variables that were analyzed from reports provided by study hospices
included, but not compared with NHPCO data were net operating revenues, physician,
nursing salary, bereavement costs, DME costs and inpatient unit costs. Net operating
revenues of the Ohio hospices ranged from a minimum of $500,000/ hospice to $13.8
million/ hospice. The difference in net operating revenues (NOR) was very high,
suggesting a possibility that a few hospices were run on a smaller scale as compared to
other hospices, where the NOR were in millions. Four out of five hospices had inpatient
units and the inpatient unit (IPU) operating costs varied from $700,000/ hospice to $1.7
million/ hospice. Average physician salary was lower than average nursing salary because
these salaries reflect on the total expenditures made by the hospice on physician salary
and nursing salary. Hospice interdisciplinary team typically consists of one physician; but
approximately 10 to 20 nurses, which justifies a higher proportion of expenditure on
nursing salaries.

Approximately 1,020 different drugs under 246 therapeutic classes were utilized
in the five hospices. The most frequently utilized therapeutic class of drugs, based on
prescription drug volume included analgesic-narcotics (15.6%) followed by laxativescathartics (7.5%), and anti-anxiety drugs (7%). These results are self-explanatory as
mentioned in Chapter 1, because hospice care is primarily focused on pain and symptom
management, and in making the patient feel comfortable. When analyzing therapeutic
95

classes contributing to the majority of drug expenditures, it was found that these included
analgesics-narcotics (16.5%), SSRIs (4.7%), and anti-anxiety drugs (4.5%). Since the
utilization of analgesics, narcotics and anti-anxiety drugs is very high, the medication
expenditure in these classes is also very high. However, laxatives-cathartics, which
followed second for utilization was not observed as a major expenditure contributor. This
may be because laxatives-cathartics are relatively inexpensive drugs. SSRIs were found
to be the major contributor to expenditures. To explain this, further analyses for analyzing
each highly utilized therapeutic classes were conducted.

Upon analyzing, analgesics-narcotics, it was observed that morphine sulfate and
methadone were the two most frequently utilized medications [morphine (31.7% utilization, 25.2% - expenditure), methadone (18.9%, 5.1%) and oxycodone (11.4%,
20.3%)]. Fentanyl contributed to 22% of analgesic-narcotic expenditure; however, its
utilization was only 5.6%. Methadone is very frequently utilized; however the percentage
of expenditure it contributes to total analgesics-narcotics is very low. Such cost-effective
medications should be highly recommended for utilization. Under laxatives-cathartics,
the most frequently utilized medications included senna, docusate sodium, senna S. These
medications have very low prices, hence, laxatives-cathartics are not found as a major
contributor to expenditures. However, for therapeutic class SSRI, medications that
contributed to major utilization as well as high expenditure rates included sertaline
(40.1% utilization, 44% expenditure), citalopram (20.6%, 6.9%), paroxetine (17.2%,
19.7%), and escitalopram (17%, 22%). Sertraline and escitalopram are expensive
medications contributing to major expenditure to the hospices.
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Medications whose frequency of use accounted for high expense included
morphine sulfate (5.3% - utilization, 4.4% - expenditure), lorazepam (4.4%, 3.1%.),
furosemide (4%, 0.6%), methadone (3%, 0.9%), and prednisone (3.1%, 0.5%). These
medications fall under the highly utilized therapeutic classes. They explain the most
frequent utilization of the therapeutic classes. Furthermore, medications such as
Enoxaparin injections whose frequency of utilization was low (0.01%), contributed to
3.1% of total medication expenditure. Likewise, fentanyl and oxycodone contributed to
3.5% and 3.7%, respectively to the total medication expenditure, but their frequency of
utilization was only 0.9% and 1.9%, respectively. Such medications that do not prove to
be cost-effective, should be reviewed by pharmacists and their utilization should be
minimized.

Furthermore, medications whose frequency of use accounted for high expense
were analyzed within the identified therapeutic classes. For therapeutic class analgesicnarcotics, medications whose frequency of use contributed to major expenses were
morphine (31.7% - utilization, 25.2% - expenditure), methadone (18.9%, 5.1%) and
oxycodone (11.4%, 20.3%). Fentanyl contributed to 22% of analgesic-narcotic
expenditure, however, its utilization was only 5.6%. Medications under therapeutic class
laxatives & cathartics included senna (36.7% of expense), senna plus (11.4%) and
docusate sodium (9.5%). Similarly, medications for treatment of anxiety, which
contributed to approximately 90% of expenses, were lorazepam (60.2% - utilization,
64.2% - expenditure), alprazolam (29.8%, 15.8%), and lorazepam intensol (6.3%,
14.1%).
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Overall, comparing the medication PPPD costs of study hospice with nationwide
hospices, it was found that costs for medications at study hospices were low. This result
could be attributed to the fact that the study hospices employ pharmacists for medication
review. Hence, the utilization of cost-effective medications such as methadone and
citalopram is high, while utilization of costly agents such as fentanyl, oxycodone and
enoxaparin injections is low.

CONCLUSION OF THE STUDY

Health expenditures in the United States neared $2.3 trillion in 2007, over
ten times the $256 billion spent in 1980. 66 Prescription drugs have been the fastestgrowing component of health care costs. In 2007, prescription drug expenditures grew to
$236 billion, which is over twenty times of $12 billion expenditures in 1980s 66

Prescription drug costs are rising because of the availability of more expensive
and new drugs (accounting for 38% of the cost increase), greater overall utilization of
prescription drugs (44%), and drug price inflation (18%).4 The increase is further fueled
by the aging of the baby boom generation, the largest U.S. population cohort, that are
beginning to suffer the chronic illnesses of old age. Additionally, many drug
manufacturers use direct-to-consumer advertising to stimulate demand for new and more
expensive drug products. With the advent of newer drugs every year and the
pharmaceutical world now stepping into the very expensive, specialty drugs, the need for
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research to evaluate cost-effective medications has become imperative. It has become
necessary to find and employ new interventions to control the costs of such products.
These high costs prove to be burdensome on patients, and the society, as a whole, and
essential steps should be taken to lever such situation.

This study suggests that pharmacists led interventions are a useful way to lower
the costs and recommend cost-effective medications for patients. Pharmacists are an
important link to physician/patient relationship. The present study aimed at identifying
medications and therapeutic classes that contributed to majority of the expenditure and
utilization in hospices that utilize clinical pharmacists for drug utilization review. It was
found the pppd costs in the study hospices were lower than pppd costs for hospices
nationally. This proves the fact that pharmacist led interventions such as medication
review has the potential to bring cost savings.

In this study, the five study hospices employ preferred drugs recommended by
pharmacists following a medication review to identify potential drug related problems
(DRPs) and encourage cost-effective drug utilization. As a result of these interventions,
the utilization of medications such as fentanyl patches, enoxaparin injections and
oxycodone is low. Use of medications such as methadone, alprazolam, prednisone,
citalopram should be recommended.

The overall costs for hospice care to Medicare, other third party payers and
patients may be less as compared to the costs incurred by conventional care, but the most
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important element to hospice care, the cost for medications (8% - 40% of net operating
revenues) still holds opportunity to be minimized. Especially, with the introduction of
Patient Protection plan (2010) and ACA, and the new hospice payment rules, phase-out
of Budget Neutrality Adjustment Factor (BNAF) will be implemented, leading to a
reduction in market basket update. Due to this, it has been estimated that median
Medicare profit margin for the hospice industry could decrease from 4% in 2008 to -11%
by 2019. This could severely affect hospices that serve rural patients, leading to an
overall negative profit margin in 66% of hospices by 2019. This will result to tremendous
difficulty in operation of hospice care. Therefore, hospice care needs to discover every
opportunity to strategize the reduction in costs incurring in serving the patients. 67

Pharmacists specializing in hospice and palliative care are able to recommend
appropriate and effective drug therapy as an alternative to high cost, high risk
medications and produce cost-savings; also identify DRPs which have the potential to
influence better patient outcomes. Hospices throughout the nation should consider putting
into effect such interventions made by pharmacists and place emphasis on the utilization
of cost effective drugs that can be used among terminally ill patients to provide a high
level of quality care with fiscal responsibility.

PBMs are a very important link between the pharmaceutical manufacturers,
suppliers and the institutions providing health care services. On the basis of drug
utilization research (DUR) and cost-effectiveness research, PBMs are able to make
changes to the drug formulary. They help in providing patients and the institutions such
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as hospices with appropriate medications-the foundation for selection of medications
being medication review by pharmacists. Thus, assisting hospices in achieving cost
savings, along with a high quality of clinical effectiveness.

IMPLICATIONS OF THE STUDY

This study is important for 2 main reasons: this study provides information on
cost savings produced by pharmacist-led interventions such as medication review in
hospice care; and analyzes all the important medications utilized in hospice care. There is
a dearth in literature regarding information on medications costs and utilization in
hospice care. This study will demonstrate as a benchmark for nationwide hospices for
information on medications used in hospice care.

LIMITATIONS OF THE STUDY

The study has some potential limitations. Firstly, the inherent limitations of a
retrospective database are applicable to this study as well. Retrospective databases are
often questioned in terms of validity because of possible issues with misclassification
bias, selection bias, confounding factors, sponsorship, data quality, and privacy. Secondly,
the claims data have their own limitations for conducting the study. Claims data are also
questioned since they don’t provide enough of the information researchers need to
develop and improve evidence-based guidelines. Furthermore, literature suggests that
bias promoted by the insurance industry by encouraging and supporting the adage "less is
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more" may make claim’s data unreliable.

Based on the nature of the data available, only exploratory and descriptive type of
research designs were used in the study. Patient-level claims data would have been ideal
to research further into demographic factors affecting or driving the medication costs at
hospice care. Furthermore, data for only five hospices were analyzed, making it difficult
to generalize the results to an entire population.

For comparison of medication costs, previous published data from studies have
been utilized to give an overall idea for the cost savings produced pharmacist led
interventions, assuming that all hospices that participated in previous published studies,
were a mix of hospices that employ pharmacists led intervention and those that do not
employ pharmacist led interventions. The results would prove more appropriate and
robust, if PBM claims data for hospices that do not use pharmacists interventions were
utilized to compare with our study hospices that employ pharmacist’s interventions.

In this study, reports provided by hospices have been utilized as resource to
understand hospice and patient related characteristics. Hence, robust statistical analyses
were not conducted. From, statistical point of view, analysis such as regression and power
analysis can be conducted to find the relationship between medication utilization and
patient/hospice-related variables. Results show that length of service (LOS) at hospice
care is highly skewed, to further study the LOS and the factors that affect LOS, survival
analysis would be very beneficial.
102

REFERENCES

1. NHPCO: Facts and figures. November 2001 edition. http://www.nhpco.org
Accessed on Jan 17, 2008.
2. Birnbaum SG, Kidder D. What does hospice cost? Am J Public Health.
1984;74(7):689-97.
3. Hospice in California: A look at cost and quality. Available at:
http://www.chcf.org/documents/hospitals/HospiceSnapshotCostQuality06.pdf.
Accessed on Feb 3, 2008.
4. What is hospice care? American Cancer Society. Available at:
http://www.cancer.org/docroot/ETO/content/ETO_2_5X_What_Is_Hospice_Care.
asp. Accessed on Jan 18, 2008.
5. Hoyer T. A history of Medicare hospice benefit. The Hosp J.1998;13:61-9.
6. Mor V, Kidder D. Cost savings in hospice: final results of the national hospice
study. Health Serv Res. 1985;20(4):407-422.
7. Pyenson B, Connor SR. Medicare cost in matched hospice and non-hospice
cohorts. J Pain Symp Man. 2004;28(3):200-210.
8. Greer DS. An alternative in terminal care: Results of the National Hospice Study.
J. Chronic Dis. 1998; 39(1): 9-26.
9. Stuart B, Alexander K, Arenella C. et al. Medical Guidelines for Determining
Prognosis in Selected Non-Cancer Diseases, National Hospice Organization,
1996.
10. Jacox A, Carr D, Payne R., et al. Clinical Practice Guideline. No. 9 AHCPR
103

Publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and
Research, U.S. Department of Health and Human Services. Management of
Cancer Pain. 1996.
11. Kutner JS, BlakeM, Meyer SA. Predictors of live hospice discharge. Data from
the National Home and Hospice Care Survey (NHHCS). Am J Hosp Palliat Care
2002;19:1–7.
12. Haupt BJ. Characteristics of hospice care discharges and their length of service:
United States, 2000. Vital Health Stat. 2003;2:1–36.
13. Fainsinger R et al. Symptom control during the last week of life. J Palliat Care,
1991;7(1):5-11.
14. American Academy of Hospice and Palliative Medicine. www.aahpm.org.
Accessed on December 2008.
15. Steinhauser KE, Christakis NA, Clipp EC et al. Preparing for the end of life:
Preferences of patients, families, physicians, and other care providers. J Pain
Sympt Manage 2001;22:727–737.
16. Singer PA, Martin DK, Kelner M. Quality end-of-life care. Patients’ perspectives.
JAMA 1999;281:163–168.
17. Pearlman RA. Variability in physician estimates of survival for acute respiratory
failure in chronic obstructive pulmonary disease. Chest 1987;91:515– 521.
18. Forster LE, Lynn J. Predicting life span for applicants to inpatient hospice. Arch
Intern Med 1988;148:2540–2543.
19. Lynn J, Harrell F, Cohn F et al. Prognoses of seriously ill hospitalized patients on
the days before death: Implications for patient care and public policy. New Horiz
104

1997;5:56–61.
20. Joy R. National Home and Hospice Care Survey Public-use Data File. National
Center for Health Statistics, Caring for the Dying Patient and the Family. 1983;
138.
21. Connor SR. Hospice: Practice, Pitfalls, and Promise. 1998;(2):41-45.
22. Lewis MJ. Medicine and Care of the Dying: A Modern History. Oxford University
Press US. 2007; 20.
23. Poor B; Gail P. Nursing Care at last stages of life. End of Life Nursing Care.
2001; 121.
24. Nowels D, Kutner JS, Kassner C. Hospice pharmaceutical cost trends. Am J of
Hosp and Palliat Med, 2004;(2):297-302.
25. Portenoy RK, Kanner RM, Nonopioid and adjuvant analgesics. Pain
Management: Theory and Practice.1996; 220-221.
26. Mohamed SA, Mohamed K, Borsook D. Choosing a pharmacotherapeutic
approach: nonopioid and adjuvant analgesics. The Massachusetts General
Hospital Handbook of Pain Management. 1996; 80-82.
27. Kaiko RF, Foley KM, Grabinsky P et al: Central nervous system excitatory
Effects of meperidine in cancer patients. Ann Neurol 1983; 13:180.
28. Nimmo WS, Duthie DJ. Plasma fentanyl concentrations after transdermal or IV
infusion of fentanyl (abstract). Anesthes.1986; 65: 559.
29. Arner S, Arner B. Differential effects of epidural morphine in the treatment of
cancer related pain. Acta Anaesthes Scanda 1985; 29:32.
30. Buchheit T, Rauck R. Subarachnoid techniques for cancer pain therapy: when,
105

why, and how? Curr Rev Pain 1999; 3(3): 198-205.
31. Arbit E. Neurosurgical considerations and options for cancer-related pain:
Assessment and Treatment of Cancer Pain. Progress in Pain Research and
Management, 1998; 2: 216-217.
32. The American Academy of Pain Medicine. www.painmed.com. Accessed
December 2008.
33. Spratt J, Rhonda H, Robert H. Home Health Care: Principles and Practices. Curr
Rec Cur. 1996; 147.
34. Foley KM, Herbert H. The Case Against Assisted Suicide: For the Right to Endof-life Care. 2002; 281.
35. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic
variable for survival in lung cancer. Cancer 1991;67:3131–3135.
36. Tamburini M, Brunelli C, Rosso S et al. Prognostic value of quality of life scores
in terminal cancer patients. J Pain Sympt Manage 1996;11:32–40.
37. Mossey JM, Shapiro E. Self-rated health: A predictor of mortality among the
elderly. Am J Public Health 1982;72:800–808.
38. Bruera E, Miller MJ, Kuehn N et al. Estimate of survival of patients admitted to a
palliative care unit: A prospective study. J Pain Sympt Manage 1992;7: 82–86.
39. Medicare Benefit Policy Manual Chapter 9 - Coverage of Hospice Services
Under Hospital Insurance. CMS June 2008. Available at:
http://www.cms.gov/manuals/Downloads/bp102c09.pdf Accessed November
20011.

106

40. ASHP Statement on the Pharmacist’s Role in Hospice and Palliative Care. Am J
Health-Syst Pharm. 2002; 59:1770-3.
41. Summary of Medication Management Requirements in New CMS Conditions of
Participation for Hospice Programs. Centre for Medicare and Medicaid Services
(CMS), 2007; Available at:
http://www.cms.hhs.gov/CFCsAndCoPs/Downloads/CMS3844F.pdf , Accessed
on January 2009.
42. Comprehensive Drug Abuse Prevention & Control Act of 1970. Wikipedia.
Accessed on December 2008.
43. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness
analysis, and formulary decisions. Soc Sci Med. 1998;302-3008.
44. Birnbaum HG, Kidder D. What does hospice cost? Am J Public Health. 1984
Jul;74(7):689–697.
45. Mor V, Birnbaum HG. Medicare legislation for hospice care: implications of
national hospice study data. Health Aff. 1983 2(2):80–90.
46. Vrinig BA, Kind S, McBean M. Geographic Variation in Hospice use Prior to
Death. J Am Geriat Soc. 2000; 48:1117-1125.
47. Greiner KA, Perera S. Hospice Usage by Minorities in the Last Year of Life:
Results from the National Mortality Followback Survey. J Am Geriat Soc. 2003;
51(7):970-978.
48. Frantz TG, Lawrence JC, Somov PG. Factors in Hospice Patients Length of Stay.
Am J Hosp Palliat Med.16(2):449-454.
49. Gilbar O. Length of Cancer Patient Stay at Hospice: Does it affect psychological
107

adjustment to the loss of spouse. J Palliat Care.1998;14 (4):16-20.
50. Virnig BA, McBean MA, Kind S. Hospice use before Death. Medical Care:
Varibility across Cancer Diagnoses. 2002;40(1):73-78.
51. National Hospice and Palliative Care: hospice in America. 2006. Accessed on
January 2009.
52. Hospice Association of America (HAA) www.nahc.org. Accessed November
2008.
53. Birnbaum HG, Kidder D, What does Hospice Cost? Am. J. Public Health.
1984:689-97.
54. Joranson DE. Trends in Medical Use and Abuse in Opioid Analgesics. Am Med.
Assoc.2008; 283:1710-1714.
55. Hartung DM, Middleton L, Haxby DG et al. Rates of Adverse Events of LongActing Opioids in a State Medicaid Program. Ann Pharmacother. 2007;41:921928.
56. Rosseau PC. Palliative Sedation in the Management of Refractory Symptoms. J
Support Oncol. 2004; 2:185.
57. Weitzner MA. Symptom Management Issues in Hospice Care. Am J. Hosp Palliat
Care.1997; 14(5):190-195.
58. Sykes NP. The Relationship between Opioid Use and Laxative Use in Terminally
Ill Cancer Patients. Palliat Med.1998; 12(5):375-382.
59. Casey P. Depression in the dying – disorder or distress. Prog Palliat Care 1994; 2:
1–3
60. William ML, Friedman T, Rudd N. A Survey of Anti-depressant prescribing in
108

Terminally Ill. Palliat Med. 1999; 13:243-248.
61. Haughtvedt CL, MacKeigan LD, Birdwell SW. Cost of providing pharmaceutical
services to hospice patients. Am J. Health-Syst Pharm. 1995; 52(21):2419-2412
62. Nowels DE, Kutner JS, Kassner C. Hospice pharmaceutical cost Trends. Am J
Hosp Palliat Care, 2004; 21(4):297-302.
63. Lee J; McPherson ML. Outcomes of Recommendations by Hospice Pharmacists.
Am J Health-Syst Pharm. 2006;63(22):2235-2239.
64. Guignard PA. Economic Impact of Pharmacists’ Interventions with Non Steroidal
Inflammatory Drugs. Ann Pharmacother. 37(3):332-338.
65. Connor SR, Development of Hospice and Palliative Care in the United States.
Omega: J Death and Dying. 2008:56(1):89-99.
66. Centers for Medicare and Medicaid Services, Office of the Actuary, National
Health Statistics Group, National Health Care Expenditures Data, January 2012.
67. Summary of Profit Margin Analysis for Urban and Rural Hospices.
Http://www.nhpco.org/sites/default/files/public/public_policy/Profit-MarginSummary.pdf. Accessed June, 2012.

109

CURRICULUM VITAE
RACHI H. PAREKH
Email: rachi145@gmail.com
RESEARCH INTERESTS
Market research using data, Secondary databases, Health economics and pharmacoeconomic evaluations,
and Health outcomes research.
PROFESSIONAL EDUCATION
2013
Master of Pharmacy Administration (Degree to be awarded in May 2013)
Dept. of Pharmacy Administration, Duquesne University, Pittsburgh, PA.
2005

Bachelor of Pharmacy (B. Pharm)
Modern College of Pharmacy, Pune University – Pune, India.

WORK EXPERIENCE
Feb 2009 – Feb 2010
Healthcore Inc., Wilmington, DE.
Job Profile: Health Economics & Outcomes Research Analyst

Performing prospective and retrospective health economic research activities.

Conducting statistical analysis for research projects using SAS.

Supporting research activities for Health Outcomes project managers in research designs, and
analytical techniques.
June 2008 – Sept 2008




Novartis Pharmaceuticals, New Jersey, USA.
Job Profile: Outcomes Research Intern
Assisted in project development related to diseases such as hypertension and diabetes using
database and interpreted results.
Assisted in project development related to cigarette smoking using database, conducted analysis
and interpreted results.
(Results to be presented at a conference)
Conducted review on Health Related Quality of life (HRQoL) instruments used in patients with
cognitive dementia and hypertension

Oct 2004 – Nov 2004
Internship at Baroque Pharmaceuticals, Gujarat, India.

Undergone training in chemical and instrumental analysis of raw materials, finished products, and
manufacturing departments of tablet, capsule and liquid dosage forms.
PUBLICATIONS
1.
Parekh R, Rane P, Kamal KM. Pill Box: Enhancing physician pharmacist communication: A step
towards reducing medication errors. The Bulletin-Allegheny County Medical Society. Nov, 2007:508-512.
2.
Kamal KM, Desselle SP, Rane P, Parekh R, Zacker C. Content analysis of FDA warning letters to
manufacturers of pharmaceuticals and biologicals. Drug Information Journal. July, 2009:385-393
SCIENTIFIC PRESENTATIONS
1.
Impact of Pharmacist-Led Intervention on Medication Costs and Utilization in hospice care: A
Claims Data Analysis. National Hospice and Palliative Care Organization (NHPCO’s) 10th Clinical Team
Conference, Facility-Based Hospice Forum, Scientific Symposium and Pediatric Intensive: Soaring to New
Heights in Interdisciplinary Care to be held in Denver, CO from September 22– 26, 2009.
2.
Kamal KM, Rane P, Parekh R, Desselle SP, Zacker C. Content Analysis of FDA warning letters
and notices to manufacturers of pharmaceuticals concerning health outcomes- related promotional claims
violations. Annual meeting of the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR), Toronto, Canada, May 2008.

110

3.
Parekh R, Rane P, Kamal KM, Desselle SP, Zacker C. Content Analysis of FDA Warning Letters
to Manufacturersof Pharmaceuticals and Biologics. Academy of Managed Care Pharmacy (AMCP),
Boston, MA, Oct 2007.
4.
Parekh R, Kamal KM. Smoking status and pneumonia immunization: Findings from the 2005
Behavioral risk factor surveillance system (BRFSS) data. Annual meeting of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, May 2007. Abstract published in
Value in Health. May/June 2007.
5.
Parekh H, Parekh R, Rane P, Desselle S. A content analysis of advertisements for pharmacist
positions: Employers’ use of intrinsic and extrinsic motivational appeals. Annual meeting of the American
Pharmacists Association (APhA), Atlanta, GA, March 2007.
RESEARCH GRANTS
Funding Source: Novartis.
1.

Title: Consequences of pharmacy benefits design: An examination of clinical, economic, ethical,
and humanistic considerations.
Role/Date: Research Assistant, December 1, 2006 to June 1, 2007.
Responsibilities included literature search, preparation of report, publication of results.

2.

Title: Content analysis of FDA warning letters to Manufacturers of Pharmaceuticals and Biologicals.
Role/Date: Researcher, December 1, 2006 to June 1, 2007.
Responsibilities included literature search, preparation of coding sheet, judging the warning
letters, entering data into SPSS and conduct statistics, preparation of report, publication of results.

COMPUTER SKILLS
Statistical packages:
Decision analysis software:
Other:

SPSS, SAS-JMP, SAS
DATA TreeAge, Microsoft Excel, Microsoft Access
MS Office, Microsoft FrontPage

PROFESSIONAL MEMBERSHIP
2007 – Present
Member of American Society of Health Economists (ASHE)
2007 – Present
Member of International Society for Pharmacoeconomics & Outcomes Research
(ISPOR)
2007 – Present
Member of the American Pharmacists Association (APhA)

111

